Prognostic Value of Ciculating Pregnancy-Associated Plasma Protein-A (PAPP-A) and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels in Patients with Chronic Stable Angina Pectoris by Consuegra Sánchez, Luciano
 DEPARTAMENT DE MEDICINA 
 
 
 
 
 
 
 
 
 
 
PROGNOSTIC VALUE OF CIRCULATING PREGNANCY-
ASSOCIATED PLASMA PROTEIN-A (PAPP-A) AND 
PROFORM OF EOSINOPHIL MAJOR BASIC PROTEIN 
(PRO-MBP) LEVELS IN PATIENTS WITH CHRONIC 
STABLE ANGINA PECTORIS. 
 
 
 
 
 
 
 
 
LUCIANO CONSUEGRA-SÁNCHEZ 
 
 
 
 
 
 
UNIVERSITAT DE VALÈNCIA 
Servei de Publicacions 
2010 
 
 
 
Aquesta Tesi Doctoral va ser presentada a València el dia 20 de 
gener de 2010 davant un tribunal format per: 
 
- Dr. Cándido Martín Luengo 
- Dr. José Millet Roig 
- Dr. Jose María Cruz Fernández 
- Dr. Alfredo Bardají Ruiz 
- Dr. Francisco Javier Chorro Gascó 
 
 
 
Va ser dirigida per: 
Dr. Juan Sanchis Forés 
 
 
 
 
 
 
©Copyright: Servei de Publicacions 
Luciano Consuegra-Sánchez 
 
 
 
 
 
 
 
Dipòsit legal: V-1062-2011 
I.S.B.N.: 978-84-370-7798-7 
Edita: Universitat de València 
Servei de Publicacions 
C/ Arts Gràfiques, 13 baix 
46010 València 
Spain 
   Telèfon:(0034)963864115 
1 
 
 
                      
Departament de Medicina 
 
  
“Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A 
(PAPP-A) and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels in 
Patients with Chronic Stable Angina Pectoris” 
 
“Valor Pronóstico de los Niveles de Proteína Plasmática Asociada a Embarazo A circulante 
(PAPP-A) y Proforma de la Proteína Eosinofílica Básica Mayor (pro-MBP) en Pacientes con 
Angina Crónica Estable” 
 
 
Luciano Consuegra Sánchez 
 
UNIVERSITAT DE VALÈNCIA 
Servei de Publicacions 
2010
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 
2 
 
 
 
 
Aquesta Tesi Doctoral va ser presentada a València el dia 20 de Enero 
de 2010 davant un tribunal format per: 
 
- D. Cándido Martín Luengo 
- D. Francisco Javier Chorro Gascó 
- D. José María Cruz Fernandez 
- D. José Millet Roig 
- D. Alfredo Bardaji Ruiz 
 
Va ser dirigida per: 
D. Juan Sanchis Fores 
 
 
 
 
 
 
 
 
 
 
 
 
©Copyright: Servei de Publicacions 
Luciano Consuegra Sánchez 
Depòsit legal: 
I.S.B.N.: 
Edita: Universitat de València 
Servei de Publicacions 
C/ Artes Gráficas, 13 bajo 
46010 València 
Spain 
Telèfon:963864115
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 3
INDEX. 
 Page/s 
 
1. Dr. Juan Sanchis’ letter (Director). 
 
7 
2. Endorsement letters by Prof. G.Ambrosio & Prof. D. Holt. 
 
9-11 
3. Mentions. 
 
12-16 
4. Abreviations and Acronyms. 
 
17-18 
5. Abstract. Keywords. 19-20 
 
6. Resumen. Palabras clave. 
 
21-23 
7. The Inflammatory Hypothesis. 
 
24-44 
   7.1. The “response to injury” concept. 
 
24-27 
   7.2. The “intimal thickenings”. 
 
27-29 
   7.3. From fatty streak to “overt atherosclerotic plaque”. 
 
29-33 
   7.4. The “advanced atherosclerotic plaque”. 
    
34-37 
   7.5. Plaque rupture & the Acute Coronary Event. 
 
37-40 
   7.6. The “inflammatory hypothesis”. 
 
40-42 
   7.7. Biomarkers vs. “mediators” of disease. 
 
43-44 
8. Chronic Stable Angina. 
 
45-51 
   8.1. Definition and importance of risk stratification. 
 
45-47 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 4 
   8.2. Risk stratification. 
 
47-49 
     8.2.1. Echocardiography. 
 
47 
     8.2.2. Stress testing. 
 
48 
     8.2.3. Coronary arteriography. 
 
48-49 
8.3. Conclusions. 
 
49-51 
9. Overview of the value of Pregnancy Associated Plasma 
Protein-A (PAPP-A) and Cardiovascular Risk. 
52-73 
   9.1. PAPP-A and stable atherosclerotic disease:  
                                   .Coronary artery disease. 
 
54-55 
   9.2. PAPP-A and stable atherosclerotic disease:     
                                   .Carotid and peripheral arterial  
                                    diseases.                                                                 
56-57 
   9.3. Prognostic value in patients with stable atherosclerotic                 
          disease. 
 
57 
   9.4. PAPP-A and lipids. 
 
57-58 
   9.5. PAPP-A and the acute coronary syndrome: diagnostic 
          value. 
58-61 
   9.6. PAPP-A and the acute coronary syndrome: kinetics of 
          PAPP-A. 
61-62 
   9.7. Prognostic value in the acute coronary syndrome. 
 
62-64 
   9.8. PAPP-A and plaque instability: cause or consequence? 64-67 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 5
 
   9.9. Biochemical considerations. 
 
67-70 
   9.10. Statistical considerations. 
 
70-72 
   9.11. General conclusions. 
 
72-73 
10. Original Research: “Prognostic Value of Circulating 
Pregnancy-Associated Plasma Protein–A (PAPP-A) and 
Proform of Eosinophil Major Basic Protein (pro-MBP) 
Levels in Patients with Chronic Stable Angina Pectoris”.  
74-103 
   10.1. HYPOTHESIS. Rationale and Objectives. 
 
74-75 
   10.2. METHODS. 
 
76-83 
     10.2.1. Patients. Inclusion and exclusion criteria.  
 
76-77 
     10.2.2. Study endpoint. Follow-up. Variables’ definitions. 
 
77-78 
     10.2.3. Angiographic analysis. 
 
78-80 
     10.2.4. Biochemical measurements. 
 
80-81 
     10.2.5. Statistical analysis. 
 
82-83 
   10.3. RESULTS. 
 
84-91 
     10.3.1. Baseline Characteristics. 
 
84-86 
     10.3.2. Events during follow-up and Univariate Analysis. 
 
86 
     10.3.3. Multivariate Analysis. 87-88 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 6 
 
  10.3.4. Calibration. Discrimination. Bootstrapping. 
88-90 
  10.3.5. Prognostic value of pro-MBP and PAPP-A/ 
              proMBP ratio. 
 
90 
10.4. DISCUSSION. 
 
91-97 
10.5. CONCLUSIONS. 
 
98-99 
10.6. CONCLUSIONES FINALES. 
 
100-101 
10.7. ACKNOWLEDGEMENTS. 
 
102-103 
10.8. REFERENCES LIST. 
 
104-143 
10.9. TABLES (1 to 6). 
 
144-152 
10.10. FIGURES (1 to 15). 
 
153-167 
    
  
 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 7
 
 
El Dr. Juan Sanchis Forés, Jefe Clínico de Cardiología del Hospital 
Clínico de Valencia. 
 
   CERTIFICA: 
  
Que D. Luciano Consuegra Sánchez, con Grado de Licenciado en 
Medicina y Cirugía, ha realizado bajo mi dirección el trabajo para la 
elaboración de su Tesis Doctoral titulada: “Prognostic Value of 
Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) and 
Proform of Eosinophil Major Basic Protein (pro-MBP) Levels in 
Patients with Chronic Stable Angina Pectoris”.  
 
 Tras su redacción, la presente memoria ha sido revisada por mí, 
encontrándola conforme para ser presentada y aspirar al grado de 
Doctor en Medicina (“Doctor Europeus”) ante el tribunal designado. 
 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 8 
 Para que conste, en cumplimiento de las disposiciones vigentes, 
expido el presente documento en Valencia a 1 de Septiembre de 2009. 
 
Fdo. Dr. Juan Sanchis Forés. 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 9
 
                                     UNIVERSITÀ E AZIENDA OSPEDALIERA DI PERUGIA 
                                     Cardiologia 
                                                      e 
                             Fisiopatologia Cardiovascolare 
Direttore 
Prof. Giuseppe Ambrosio 
 
To whom it may concern      
  October 14, 2008 
 
RE: Luciano Consuegra Sánchez, MD 
 
This letter is to support Dr. Luciano Consuegra Sánchez' application for 
the degree of European Doctor.  
 
I have read his thesis “Prognostic Value of Circulating Pregnancy-
Associated Plasma Protein–A (PAPP-A) and Proform of Eosinophil Major 
Basic Protein (pro-MBP) Levels in Patients with Chronic Stable Angina 
Pectoris”. The thesis concerns the measurement of concentration of a 
biomarker, pregnancy-associated plasma protein A, in human blood, 
and its association with coronary artery disease progression in patients. 
It is the results of obviously intense work, performed with state of the 
art methodologies in collaboration with investigators who have long 
standing interest and solid reputation in the field of biomarker assay 
and cardiovascular disease. 
 
In my opinion, this is an original and interesting piece of work, the 
results of which have potentially relevant implications with respect to 
prognostic stratification of patients with coronary artery disease, and to 
management of this frequent and clinically important conditions. 
Results from this endeavor have been presented at major international 
cardiology meetings, and published in peer-reviewd cardiology journals. 
I have no reservations in recommending the thesis for the award of 
European Doctor. 
 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 10 
Please, do not hesitate in contacting me if I can be of further help with 
this application. 
Sincerely, 
 
Giuseppe Ambrosio, M.D., Ph.D., FESC, FACC, FAHA 
Director 
Division of Cardiology 
University of Perugia School of Medicine 
Ospedale Silvestrini 
Via S. Andrea delle Fratte 
06156 Perugia, ITALY 
ph: +39 075 527 1509 
fax:   +39 075 527 1244 
e-mail: giuseppe.ambrosio@ospedale.perugia.it 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 11
 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 12 
3. MENTIONS. 
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Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) and Proform of 
Eosinophil Major Basic Protein (pro-MBP) Levels in Patients with Chronic 
Stable Angina Pectoris. J Am Coll Cardiol 2007;49(supplement 2);9:B1-B60). 
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4. ABREVIATIONS AND ACRONYMS. 
 
IA = Injurious agents 
LDL = Low density lipoprotein 
PG = Proteoglycans 
CSPG = Chondroitin Sulfate Proteoglycans  
ECM = Extracellular matrix 
SMC = Smooth muscle cells 
EC = Endothelial cells  
VCAM-1 = Vascular cell adhesion molecule 1 
MMP-9 = Monocyte matrix metalloproteinase 9  
IL = Interleukin  
IFN = Interferon 
HDL = High density lipoprotein  
PAI-1 = Plasminogen activator inhibitor 1  
CRP = C-reactive protein  
CSA = Chronic stable angina 
CAD = Coronary artery disease  
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ECG = Electrocardiogram  
LVEF = Left ventricular ejection fraction 
ACS = Acute coronary syndrome 
PAPP-A = Pregnancy associated plasma protein A  
ROC = Receiver operator characteristic 
hs-CRP = High sensitivity C-reactive protein 
Pro-MBP = Proform of eosinophil major basic protein 
IGF-1 = Insulin-like growth factor 1 
HR = Hazard ratio 
CI = Confidence interval 
c-Tn I/T = Cardiac troponin I/T 
CK-MB = Creatine-kinase MB isoenzyme 
OR = Odds ratio 
MI = Myocardial infarction 
SD = Standard deviation 
IGFBP = Insulin-like growth factor binding protein 
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5. ABSTRACT.  
 
Background: The search for markers to improve risk prediction for 
individuals at risk of developing serious cardiovascular events is 
ongoing. New markers of coronary artery disease progression have been 
identified in recent years, among which, circulating levels of pregnancy-
associated plasma protein-A (PAPP-A) offer an interesting profile. 
PAPP-A may play a role in the development of atherosclerotic lesions 
and represent also a marker of atheromatous plaque instability and 
extent of cardiovascular disease. PAPP-A has been shown to be a 
marker of adverse outcome in the acute coronary syndrome.  
The proform of eosinophil major basic protein (pro-MBP) is the 
endogenous inhibitor of the proteolytic activity of PAPP-A. PAPP-A 
levels and PAPP-A/pro-MBP ratio are increased in chronic stable 
angina (CSA) patients with complex coronary artery stenoses. Little is 
known however, about the long-term prognostic value of PAPP-A and 
pro-MBP in “real-life” CSA patients. We sought to assess whether 
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PAPP-A, pro-MBP and PAPP-A/pro-MBP levels predict long-term all-
cause mortality in patients with CSA. 
Methods: We recruited 663 consecutive patients (169 women [25.5 %]; 
mean age 62.9 ± 9.7 years) undergoing routine diagnostic coronary 
angiography. Samples for PAPP-A and pro-MBP were taken at study 
entry. Patients were followed for a median of 8.8 years (interquartile 
range 3 - 10.6 years). 
Results: One hundred and six patients (16 %) died during follow-up. 
On a Cox proportional hazards model, increased PAPP-A concentration 
(> 4.8 mIU/L) was an independent predictor of the occurrence of all-
cause mortality (HR 1.953, 95% CI 1.135-3.360, p = 0.016). Neither 
pro-MBP nor PAPP-A/pro-MBP ratio were markers of all-cause 
mortality (p = 0.45 and 0.54, respectively). 
Conclusions: High PAPP-A levels (> 4.8 mIU/L) showed an 
association with all-cause mortality during long-term follow-up in 
patients with CSA.  
Keywords: PAPP-A, pro-MBP, chronic stable angina, prognosis. 
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6. RESUMEN.  
 
Antecedentes: La búsqueda de marcadores para mejorar la predicción 
de individuos en riesgo de desarrollar eventos cardiovasculares está en 
marcha. Recientemente se han identificado nuevos marcadores de 
progresión de la enfermedad coronaria, entre los cuales, la proteína 
plasmática asociada a embarazo tipo A (PAPP-A) presenta un perfil 
interesante. PAPP-A podría desempeñar un papel en el desarrollo de las 
lesiones ateroscleróticas, así como representar un marcador de 
inestabilidad de placa ateromatosa y extensión de la enfermedad 
aterosclerótica. Además PAPP-A es un marcador de eventos adversos 
en el contexto del síndrome coronario agudo. 
La proforma de la proteína mayor básica eosinofílica (pro-MBP) es un 
inhibidor endógeno de la actividad proteolítica de PAPP-A. Los niveles 
de PAPP-A y del cociente PAPP-A/pro-MBP están aumentados en 
pacientes angina crónica estable que presentan lesiones coronarias 
complejas en la angiografía. Se desconoce el valor pronóstico a largo 
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plazo de los niveles de PAPP-A y pro-MBP en pacientes con angina 
crónica estable de la “práctica real”. 
Se pretendió en este estudio evaluar si los niveles de PAPP-A, pro-MBP 
y del cociente PAPP-A/pro-MBP predicen la mortalidad por cualquier 
causa a largo plazo en pacientes con angina crónica estable. 
 
Métodos: Reclutamos 663 pacientes consecutivos (169 mujeres [25.5 
%]; edad media 62.9 años ± 9.7 años) con angina crónica estable 
remitidos para angiografía coronaria diagnóstica. Se tomaron muestras 
para medir PAPP-A y pro-MBP al inicio del estudio. Los pacientes 
fueron seguidos por una mediana de tiempo de 8.8 años (rango 
intercuartílico 3 – 10.6 años). 
 
Resultados: Ciento seis (16 %) pacientes murieron durante el 
seguimiento. La concentración de PAPP-A (> 4.8 mIU/L) fué un 
predictor independiente de la mortalidad por cualquier causa (HR 1.953, 
95% CI 1.135-3.360, p = 0.016) en un modelo de riesgos proporcionales 
de Cox. Ni pro-MBP ni el cociente PAPP-A/pro-MBP fueron 
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marcadores de mortalidad por cualquier causa (p = 0.45 and 0.54, 
respectivamente). 
 
Conclusiones: En el presente estudio, los niveles altos de PAPP-A 
superiores a 4.8 mIU/L se asociaron con la muerte por cualquier causa a 
largo plazo en pacientes con angina crónica estable.  
 
Palabras clave: Proteína plasmática asociada a embarazo tipo A, 
proforma de la proteína mayor básica eosinofílica, angina crónica 
estable, pronóstico. 
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7. THE INFLAMMATORY HYPOTHESIS. 
 
7.1. The “response-to-injury” concept (Fig. 1). 
The response-to-injury hypothesis states that the initial event in the 
pathogenesis of atherosclerosis is injury to the endothelium (1). A 
variety of injurious agents (IA) produce an inflammatory response in 
which leucocytes, primarily monocytes, migrate to the area of injury 
(2). The result is retention and oxidation of lipoproteins and 
transformation of monocytes into macrophages that ingest lipid, 
particularly oxidized low density lipoproteins (LDL). These form the 
fatty streak that is an early objective sign of atherosclerosis (2). 
Important considerations in this theory are the precise nature of the IA, 
and the sequence of events that lead to the retention of lipid. Several 
studies in experimental animals have demonstrated that lipid retention 
occurs before the monocytes migrate into the intima (3), showing that 
the monocyte is not the cause of the lipid retention (4,5).  
Previous studies demonstrated that the initial lesion in atherosclerosis is 
asymmetrical intimal thickening, the result of increased production of 
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sulfate-containing proteoglycans (PGs) - primarily Chondroitin Sulfate 
Proteoglycans (CSPG) and other forms of extracellular matrix (ECM) - 
by resident intimal smooth muscle cells (SMCs) in a focal area of the 
arterial wall (6–9). The IA, directly or indirectly, enters the arterial wall 
from the circulating blood, and then either stimulates or enters the 
resident SMC, the principal source of vascular PGs (10), to produce 
increased amounts of PGs and ECM. Walton (8) showed this mucoid 
thickening of the intima occurs before lipid infiltration and is composed 
primarily of collagen, PGs and ECM. Thus, although lipid accumulation 
in the artery wall is considered an early event in atherosclerosis, lipid 
retention is not the initiating event, and the fatty streak is not the first 
sign of atherosclerotic injury (11,12). This initial intimal thickening is 
not characterized by hypercellularity or proliferation of SMCs (13), as is 
seen in other types of vascular injury (14), but rather by relative 
acellularity, apparently due to the increased amounts of PGs and ECM 
without associated SMC proliferation (15). The relative acellularity 
noted in these early lesions is not believed to be due to massive cell 
death of resident intimal cells (16). Increased production of PG and 
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ECM, without an increase in the number of SMCs, is an unusual 
response to injury, suggesting a specific type of IA and/or a specific 
type of injury or effect on the SMC (17,18). 
Whether the increase in PGs and ECM is a pathologic response and, 
therefore, to be prevented, or is a physiologic defensive, protective, or 
reparative response to the IA is not known (6,10). The fact that these 
intimal thickenings develop very early after wall injury and before lipid 
accumulation suggest this is a protective, healing, or defensive response 
(1,6). This view is supported by the knowledge that CSPG is required 
and is the predominant PG in normal wound repair (9). However, if this 
is a physiologic defence, it fails badly because the IA agent is not 
halted, proliferation of PGs and ECM continues, and resolution, healing, 
and stabilization do not occur. The disease continues to progress.  
The ECM is a visco-elastic material containing primarily CSPG, a 
biochemically active scaffold that regulates arterial permeability, 
filtration, transport of plasma constituents, and regulation of wall 
metabolism and function (10). The increased amount of PGs produced 
by the SMC in response to various growth factors associated with 
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atherosclerotic injury have much longer side chains and form larger 
aggregates than do the PGs normally found in the artery wall (10,13,19). 
Thus, there is not only an increase in the PGs and ECM produced, but a 
change in the structure of the PGs in the areas of atherosclerotic injury. 
This change in PG structure is believed to alter the metabolic properties 
and biochemical function of the PGs and ECM, resulting in a 
disturbance in the transfer of substrates through the zone of injury, 
particularly alteration of interactions with lipoproteins (10,13,19,20). 
These structural and functional changes in the PGs as well as their 
turnover rate, are directly related to the rate of retention of lipid in the 
interstices of the ECM (8,9). The alteration in structure and the 
increased production of PGs suggest a pathologic component of the 
disease process, produced and altered, not as a physiologic defence 
(2,8), but for the specific purpose of retaining lipid, particularly LDL. 
 
7.2. The “Intimal thickenings”. 
Stary et al. (21), believe many asymmetric intimal thickenings, termed 
Adaptive Intimal Thickening, reflect a physiologic adaptive response to 
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hemodynamic stress. They found this thickening at points of arterial 
bifurcation in infant human beings and animals. The authors point out 
that those physiologic thickenings may also be the site of atherosclerotic 
plaques. It may be difficult to distinguish thickenings that are 
physiologic adaptations from those that are pathologic, particularly in 
the early stages of atherosclerosis. These adaptive intimal thickenings 
are rich is PGs (21). Evidence of lipid retention, then, is a primary 
feature that distinguishes physiologic thickening from pathologic 
atherosclerosis (21). The presence of intimal thickening at points of 
bifurcation supports the view that these lesions are an adaptation to 
hemodynamic stresses, but the occurrence of the same lesions in areas 
without bifurcations, or areas of low or relatively low hemodynamic 
stress, suggests other factors are also involved. These other additional 
factors may be acting independently or in conjunction with 
hemodynamic stresses to transform adaptive intimal thickening into 
atherosclerotic lesions. The IA causing atherosclerosis appears to enter 
at a focal point in the artery wall. In some way it stimulates the resident 
intimal SMC to produce increased amounts of an abnormal form of 
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PGs, resulting in asymmetric intimal thickening and lipid retention. 
Asymmetric intimal thickenings are ubiquitous throughout the coronary 
tree because atherosclerosis is multicentric in origin and the IA, present 
in circulating blood, may enter the wall at any vulnerable point. The 
production of an abnormal form of PGs appears to be a pathologic 
component of the disease process, produced specifically to retain lipid. 
The IA appears to establish a locus or focus of injury and then spreads 
in all directions from this central focus, to contiguous areas within the 
intimal layer. Lipid-laden SMC are an early, but not the earliest sign of 
atherosclerosis. Degeneration, necrosis and calcification of plaque tissue 
can occur very early in plaque development. The defensive responses, 
whatever they may be, appear to be unable to halt, sequester, or 
neutralize the IA or to effect healing and resolution of the injured area. 
 
7.3. From “fatty streak” to “overt atherosclerotic plaque” (Fig. 2). 
Fatty streaks do not cause symptoms and may either progress to more 
complex lesions or involute. Fatty streaks have focal increases in the 
content of lipoproteins within regions of the intima, where they 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 30 
associate with components of the extracellular matrix such as 
proteoglycans, slowing their egress. This retention sequesters 
lipoproteins within the intima, isolating them from plasma antioxidants, 
thus favoring their oxidative modification (22–24). Oxidatively-
modified LDL particles comprise an incompletely defined mixture, 
because both the lipid and protein moieties can undergo oxidative 
modification. Constituents of such modified lipoprotein particles can 
induce a local inflammatory response (25). Endothelial cells (ECs) 
normally resist leukocyte adhesion. Proinflammatory stimuli, including 
a diet high in saturated fat, hypercholesterolemia, obesity, 
hyperglycemia, insulin resistance, hypertension, and smoking, trigger 
the endothelial expression of adhesion molecules such as P-selectin and 
vascular cell adhesion molecule-1 (VCAM-1), which mediate the 
attachment of circulating monocytes and lymphocytes (26–28). 
Interestingly, atherosclerotic lesions often form at bifurcations of 
arteries, regions characterized by disturbed blood flow, which reduces 
the activity of endothelial atheroprotective molecules such as nitric 
oxide and favors regional VCAM-1 expression (29). Chemoattractant 
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factors, which include monocyte chemoattractant protein-1 produced by 
vascular wall cells in response to modified lipoproteins, direct the 
migration and diapedesis of adherent monocytes (30, 31). 
Monocytic cells directly interacting with human ECs increase monocyte 
matrix metalloproteinase 9 (MMP-9) production several fold, allowing 
for the subsequent infiltration of leukocytes through the endothelial 
layer and its associated basement membrane (33). Within the intima, 
monocytes mature into macrophages under the influence of macrophage 
colony stimulating factor, which is overexpressed in the inflamed intima 
(34,35). Macrophage colony-stimulating factor stimulation also 
increases macrophage expression of scavenger receptors, members of 
the pattern-recognition receptor superfamily, which engulf modified 
lipoproteins through receptor-mediated endocytosis. Accumulation of 
cholesteryl esters in the cytoplasm converts macrophages into foam 
cells, i.e., lipid-laden macrophages characteristic of early-stage 
atherosclerosis. In parallel, macrophages proliferate and amplify the 
inflammatory response through the secretion of numerous growth 
factors and cytokines, including tumor necrosis factor and interleukin 
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(IL)-1. Recent evidence supports selective recruitment of a 
proinflammatory subset of monocytes to nascent atheroma in mice (36, 
37). These observations point to a previously unappreciated layer of 
complexity in the inflammatory aspects of early atherogenesis. T cells, 
representing the adaptive arm of the immune response, also play a 
critical role in atherogenesis, entering lesions in response to the 
chemokineinducible protein-10, monokine induced by interferon (IFN), 
and IFN-inducible T cell chemoattractant (38). The CD4 subtype, which 
recognizes antigens presented as fragments bound to major 
histocompatibility complex class II molecules, predominates in the 
lesion. Interestingly, human lesions contain CD4 T cells reactive to the 
disease-related antigens associated with oxidized LDL (39). The 
atherosclerotic lesion contains cytokines that promote a T-helper 1 
response, inducing activated T cells to differentiate into T-helper 1 
effector cells (40). These cells amplify the local inflammatory activity 
by producing proinflammatory cytokines such as IFN and CD40 ligand 
(CD40L, CD154), which contribute importantly to plaque progression. 
Adiponectin, a product of adipose tissue, has insulinsensitizing, 
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antiatherogenic, and antiinflammatory properties (41). An important 
autocrine/paracrine factor in adipose tissue, it modulates the 
differentiation of preadipocytes and favors the formation of mature 
adipocytes. Curiously, adiponectin concentrations are lower in obese 
than lean individuals. This adipokine also functions as an endocrine 
factor, influencing whole-body metabolism via effects on target organs. 
Adiponectin exerts multiple biologic effects pivotal to cardiovascular 
biology, including increasing insulin sensitivity, reducing visceral 
adipose mass, reducing plasma triglycerides, and increasing high-
density lipoprotein (HDL) cholesterol (42). Adiponectin alters the 
concentrations and activity of enzymes responsible for the catabolism of 
triglyceride-rich lipoproteins and HDL, such as lipoprotein lipase and 
hepatic lipase. It thus influences atherosclerosis by affecting the balance 
of atherogenic and antiatherogenic lipoproteins in plasma (43). 
Adiponectin also directly affects the function of endothelial cells, 
reducing VCAM-1 expression, and macrophages, decreasing the 
expression of scavenger receptors and the production of tumor necrosis 
factor (41, 44). 
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7.4. The “advanced atherosclerotic plaque”. 
Macrophages and T cells infiltrate atherosclerotic lesions and localize 
particularly in the shoulder region, where the atheroma grows. Whereas 
foam cell accumulation characterizes fatty streaks, deposition of fibrous 
tissue defines the more advanced atherosclerotic lesion. SMC synthesize 
the bulk of the extracellular matrix that characterizes this phase of 
plaque evolution (45). In response to platelet derived growth factor 
released by activated macrophages and ECs, and silent plaque 
disruptions that lead to clinically unapparent mural thrombi, SMCs 
migrate from the tunica media into the intima via degradation of the 
extracellular matrix mediated by MMP-9 and other proteinases (46). In 
the intima, SMCs proliferate under the influence of various growth 
factors and secrete extracellular matrix proteins. This process causes the 
lesion to evolve from a lipid-rich plaque to a fibrotic and, ultimately, a 
calcified plaque that may create a stenosis. Human atheromata express 
IL-18 and increased concentrations of its receptor subunits, IL-18R 
(47). IL-18 occurs predominantly as the mature 18-Kd form and 
colocalizes with mononuclear phagocytes while ECs, SMCs, and 
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macrophages all express IL 18R. Importantly, IL-18 signaling evokes 
essential effectors involved in atherogenesis, e.g., adhesion molecules 
(VCAM-1), chemokines (IL-8), cytokines (IL- 6), and matrix 
metalloproteinases (MMP-1/-9/-13). In addition, IL-18, particularly in 
combination with IL-12, is a proximal inducer and regulator of the 
expression of IFN, a major proinflammatory cytokine, during 
atherogenesis. Interestingly, IL-18 induces IFN expression not only in T 
cells (48), but also in macrophages and, surprisingly, even in SMCs, 
thus activating in a paracrine mode several proinflammatory pathways 
operating during atherogenesis (47). Neovascularization arising from 
the artery’s vasa vasorum contributes to lesion progression in many 
ways (49). It provides another portal for leukocyte entry into established 
atherosclerotic lesions (50). In addition, these fragile neovessels can 
favor focal intraplaque haemorrhage that provides a mechanism for the 
discontinuous increments seen in plaque growth. Local haemorrhage 
within the plaque in turn generates thrombin, which activates ECs, 
monocytes/ macrophages, SMCs, and platelets (51). These cells respond 
to thrombin by producing a broad array of inflammatory mediators, 
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including CD40L, RANTES (regulated on activation, normal T cell 
expressed and secreted), and macrophage migration inhibitory factor. 
These molecules further promote lesion formation and favor the 
thrombotic complications of atherosclerosis (52). Platelets also play a 
central role in the biology of atherosclerosis by producing inflammatory 
mediators such as CD40L, myeloid-related protein-8/14, and platelet-
derived growth factor, as well as directing leukocyte incorporation into 
plaques through platelet mediated leukocyte adhesion. These results 
reveal the synergism between inflammation and thrombosis in the 
pathobiology of atherothrombosis (51). CD40L plays an important role 
in this phase of atherogenesis. All the main cell types involved in 
atherosclerosis, including ECs, macrophages, T cells, SMCs, and 
platelets, express this proinflammatory cytokine as well as its receptor, 
CD40 (53). CD40 ligation triggers the expression of adhesion molecules 
and the secretion of numerous cytokines and MMPs involved in 
extracellular matrix degradation (54–56). Importantly, CD40L has a 
prothrombotic effect, inducing EC (57), macrophage (54), and SMC 
(58) expression of tissue factor, which initiates the coagulation cascade. 
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Accordingly, inhibition of CD40 signaling reduces experimental 
atherosclerosis development (59) as well as the evolution of established 
atherosclerosis (60). 
 
7.5. Plaque rupture & the Acute Coronary Event. 
Plaque rupture and the ensuing thrombosis commonly cause the most 
dreaded acute complications of atherosclerosis (Fig. 3). In many cases, 
the culprit lesion of acute coronary artery thrombosis does not produce a 
critical arterial narrowing, rendering its a priori identification using 
standard angiographic methods uncertain (61). Indeed, it now appears 
that inflammatory activation, rather than the degree of stenosis, renders 
the plaque rupture prone and precipitates thrombosis and resulting tissue 
ischemia (62). Advanced complex atheroma exhibit a paucity of SMCs 
at sites of rupture and abundant macrophages, key histological 
characteristics of plaques that have ruptured and caused fatal coronary 
thrombosis. Inflammation can interfere with the integrity of the 
interstitial collagen of the fibrous cap by stimulating the destruction of 
existing collagen fibers and by blocking the creation of new collagen 
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(63). IFN, secreted by activated T cells, inhibits collagen production by 
SMCs. T lymphocytes can also contribute to the control of 
collagenolysis. CD40L as well as IL-1 produced by T cells induce 
macrophages to release interstitial collagenases, including MMP-1, -8, 
and -13 (64). The shoulder region of plaques as well as areas of foam 
cell accumulation contain MMP-9, a member of the gelatinase class of 
the metalloproteinase family (65). Interestingly, retroviral 
overexpression of an active form of MMP-9 in macrophages induces 
morphologic appearances interpreted as plaque disruption (66). Human 
plaque analysis has revealed that MMP-9 is catalytically active and may 
thus contribute to the dysregulation of extracellular matrix that leads to 
plaque rupture during the complication of atherothrombosis (65). 
Further evidence suggests that local overexpression of MMP-9 
promotes intravascular thrombus formation through increased tissue 
factor expression and tissue factor–mediated activation of the 
coagulation cascade (67). These data support an important role for 
MMP-9 in several stages of atherosclerosis. Acute coronary syndromes 
most often result from a physical disruption of the fibrous cap, either 
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frank cap fracture or superficial endothelial erosion, allowing the blood 
to make contact with the thrombogenic material in the lipid core or the 
subendothelial region of the intima (62). This contact initiates the 
formation of a thrombus, which can lead to a sudden and dramatic 
obstruction of blood flow through the affected artery. If the thrombus is 
non occlusive or transient, it may either be clinically silent or cause 
symptoms characteristic of an acute coronary syndrome. Importantly, 
with relation to the propensity of a given plaque disruption to lead to a 
sustained and occlusive thrombus, the fluid phase of blood, most 
notably circulating plasminogen activator inhibitor 1 (PAI-1) and 
fibrinogen concentrations, may determine the fate of a given plaque 
disruption (68, 69). Indeed, impaired fibrinolysis can result from an 
imbalance between clot-dissolving enzymes and their endogenous 
inhibitors, primarily PAI-1 (70). PAI-1 belongs to the serine protease 
inhibitor superfamily (serpins) and originates from several sites, 
including the endothelium, liver, and adipose tissue (71). Experimental 
work using transgenic mice that overexpress a stable form of human 
PAI-1 demonstrates an association of chronically increased 
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concentrations of PAI-1 with age-dependent coronary arterial 
thrombosis (72).  
In summary, inflammation participates pivotally in all stages of 
atherosclerosis (73–79), from lesion initiation to progression and 
destabilization. In addition, inflammation regulates both the “solid-
state”, thrombotic potential in the plaque itself and the prothrombotic 
and antifibrinolytic capacity of blood in the fluid phase. The ominous 
presence of inflammation in atherosclerosis has prompted the evaluation 
of certain key inflammatory factors in cardiovascular risk prediction. 
 
7.6. The “inflammatory hypothesis”. 
About a decade ago, the prevailing wisdom was that conventional risk 
factors explained only about half of the risk for a myocardial infarction 
or stroke. However, most studies did not assess some of the newer lipid 
markers (such as the apolipoproteins) or measures of abdominal obesity, 
diet, or psychosocial factors and moreover did not try to quantify the 
population-attributable risk. Consequently, efforts to identify novel risk 
factors were undertaken to improve cardiovascular risk prediction.  
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The hypothesis that inflammation is a central contributor to 
atherothrombosis has stimulated sustained efforts to characterize the 
specific molecules and pathways that may be involved and to identify 
biomarkers in humans that enable detection of underlying inflammatory 
activation to improve cardiovascular risk prediction. This intriguing 
concept stimulated intense interest in further investigating the ability of 
inflammatory markers to add information for cardiovascular risk 
stratification beyond that obtained from traditional risk factors. 
Recent investigations of atherosclerosis have focused on inflammation, 
providing new insight into mechanisms of disease. Further, 
inflammatory pathways involved in both innate and adaptive immune 
responses appear to transduce many of the traditional and emerging risk 
factors for atherosclerosis (Fig. 4). Inflammatory cytokines involved in 
vascular inflammation stimulate the generation of endothelial adhesion 
molecules, proteases, and other mediators, which may enter the 
circulation in soluble form. These primary cytokines also induce 
production of the messenger cytokine interleukin-6, which stimulates 
the liver to increase production of acute-phase reactants such as C-
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reactive protein (CRP). In addition, platelets and adipose tissue can 
generate inflammatory mediators relevant to atherothrombosis. Despite 
the irreplaceable utility of plasma lipid profiles in assessment of 
atherosclerotic risk, these profiles provide an incomplete picture. 
Indeed, many cardiovascular events occur in individuals with plasma 
cholesterol concentrations below the National Cholesterol Education 
Program thresholds of 200 mg/dL for total cholesterol and 130 mg/dL 
for LDL cholesterol (boundaries in general population). The concept of 
the involvement of inflammation in atherosclerosis has spurred the 
discovery and adoption of inflammatory biomarkers for cardiovascular 
risk prediction. C-reactive protein is currently the best validated 
inflammatory biomarker; in addition, brain natriuretic peptide, soluble 
CD40 ligand, adiponectin, interleukin 18, interleukin 10, pregnancy 
associated plasma protein A, neopterin, cystatin C and matrix 
metalloproteinase 9 may provide additional information for 
cardiovascular risk stratification and prediction. 
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7.7. Biomarkers vs. “mediators” of disease: C-reactive protein as an 
example. 
The distinction between biomarkers and mediators of disease has 
proven quite confusing. A particular analyte may participate clearly in a 
pathogenic pathway but not serve as an effective biomarker. Soluble 
VCAM-1, for example, does not predict the risk of future myocardial 
infarction in apparently healthy men (79). However, research has 
repeatedly and unequivocally demonstrated the essential role of VCAM-
1 in experimental atherosclerotic lesion initiation and progression (26, 
27, 81–82). 
On the other hand, a useful biomarker may not mediate pathogenic 
processes associated with disease. In the case of CRP, the bulk of 
current evidence supports its utility as a biomarker of risk, not only in 
apparently healthy populations but also in risk stratification of 
individuals with established disease. Yet, the role of CRP as a mediator 
rests on a less secure foundation; notably, many in vitro studies with 
CRP have used extraordinarily high concentrations of the molecule, 
causing concern about endotoxin contamination or preservatives in CRP 
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preparations that might have spurious effects on cells. Experimental 
results suggest that CRP displays a direct proinflammatory effect on 
endothelial cells (83) and mediates LDL uptake by macrophages (84). 
In vivo data, both in animals and humans, suggest that CRP may 
promote processes involved in the pathogenesis of atherothrombosis, 
including dysregulation of fibrinolysis by increasing the expression and 
activity of PAI-1 (85). Recent studies have also shown that CRP 
originates not only in the liver, but also from other tissues, including 
SMCs from normal coronary arteries (86-89) and diseased coronary 
artery bypass grafts (90) as well as coronary artery endothelial cells (88-
91), which may provide an explanation for potential local actions of 
CRP. 
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8. CHRONIC STABLE ANGINA (CSA). 
 
8.1. Definition and importance of risk stratification. 
Stable angina is a clinical syndrome characterized by discomfort in the 
chest, jaw, shoulder, back, or arms, typically elicited by exertion or 
emotional stress and relieved by rest or nitroglycerin. Less typically, 
discomfort may occur in the epigastric area. It is usual to confine the 
term to the cases in which the syndrome can be attributed to myocardial 
ischaemia, although essentially similar symptoms can be caused by 
disorders of the oesophagus, lungs, or chest wall (92). Although the 
most common cause of myocardial ischaemia is atherosclerotic 
coronary artery disease (CAD), demonstrable myocardial ischaemia 
may be induced by other cardiac conditions (92).  
The long-term prognosis of stable angina is variable, and the range of 
treatment options has expanded considerably from simple symptomatic 
control to potent and often expensive strategies to improve prognosis. 
When discussing risk stratification in stable angina, risk refers primarily 
to the risk of death. The process of risk stratification serves a dual 
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purpose, to facilitate an informed response to queries regarding 
prognosis from patients themselves, employers, insurers, non-
cardiology specialists considering treatment options for comorbid 
conditions and others and secondly to assist in choosing appropriate 
treatment (92). For certain management options, particularly 
revascularization and/or intensified pharmacological therapy, prognostic 
benefit is only apparent in high risk subgroups, with limited if any 
benefit in those whose prognosis is already good. This mandates 
identification of those patients at highest risk, and therefore most likely 
to benefit from more aggressive treatment, early in the assessment of 
stable angina. 
Information on the prognosis associated with chronic stable angina is 
derived from long-term prospective population based studies, clinical 
trials of anti-anginal therapy, and observational registries, with selection 
bias, an important factor to consider when evaluating and comparing the 
available data. Irrespective of the origin of the data, the individual’s 
prognosis can vary considerably, up to 10-fold, depending on baseline 
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clinical, functional and anatomical factors, emphasizing the importance 
of careful risk stratification (92). 
 
8.2. Risk stratification. 
8.2.1. Echocardiography. 
The estimation of ventricular function is extremely important in risk 
stratification (92). Further, this technique is useful to detect or rule out 
the possibility of other disorders such as valvular heart disease or 
hypertrophic cardiomyopathy (93) as a cause of symptoms and to 
evaluate ventricular function (94) For purely diagnostic purposes, echo 
is useful in patients with clinically detected murmurs, history and 
electrocardiogram (ECG) changes compatible with hypertrophic 
cardiomyopathy or previous myocardial infarction and symptoms or 
signs of heart failure. 
One of the strongest predictors of long-term survival is probably the left 
ventricular ejection fraction (LVEF). In patients with stable angina as 
LVEF declines, mortality increases. A resting LVEF of 35% is 
associated with an annual mortality rate 3% per year (95). 
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8.2.2. Stress testing. 
The exercise ECG has been extensively validated as an important tool in 
risk stratification in symptomatic patients with known or suspected 
coronary disease. Prognostic information obtained from stress testing 
relates not only to the detection of ischaemia as a simple binary 
response, but also the ischaemic threshold, the extent and severity of 
ischaemia (for imaging techniques), and functional capacity (for 
exercise testing). Stress testing alone is insufficient to assess risk of 
future events. Risk stratification with the exercise test should be a part 
of a process that includes readily accessible data from clinical 
examination and should not take place in isolation. Thus the stress test 
is performed to provide additional information regarding the patient’s 
risk status.  
 
8.2.3. Coronary arteriography. 
Despite the recognized limitations of coronary arteriography to identify 
vulnerable plaques which are likely to lead to acute coronary events, the 
extent, severity of luminal obstruction, and location of coronary disease 
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on coronary arteriography have been convincingly demonstrated to be 
important prognostic indicators in patients with angina (96).  
Coronary arteriography is generally undertaken as part of a series of 
tests to establish a diagnosis and ascertain treatment options. Coronary 
arteriography holds a fundamental position in the investigation of 
patients with stable angina, providing reliable anatomical information to 
identify the presence or absence of coronary lumen stenosis, define 
therapeutic options (suitability of medical treatment or myocardial 
revascularization) and determine prognosis. 
 
8.3. CONCLUSIONS. 
 
The revolution in the understanding of the pathophysiology of 
atherosclerosis has focused attention on inflammation and provided new 
insight into mechanism of disease. The clinical application of the 
concept that inflammation participates in atherosclerosis has stimulated 
the adoption of biomarkers of inflammation in risk prediction and other 
applications, as noted above. Contemplation of the clinical use of 
biomarkers in the context of atherosclerotic cardiovascular disease 
requires considerable care. Evaluation of the utility of a biomarker 
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requires a clear understanding of the question being asked. Is the task to 
risk-stratify apparently well or diseased populations? Should the 
biomarker be measured serially as a target of therapy? Should the 
biomarker be used as a guide for therapy in addition to the traditional 
accepted risk factors? Each of these 3 questions requires different types 
of clinical validation. The example of inflammation in atherosclerosis 
illustrates rapid translation of basic science understanding to the clinic. 
Further studies, both in progress and on the horizon, will help evaluate 
the role of novel and emerging biomarkers in the clinical management 
of atherosclerosis and targeting of therapies. Although the circulating 
concentrations of several inflammatory mediators correlate with 
increased cardiovascular risk, few are ready for clinical practice. CRP 
attracts particular attention and has stood the test of time, although not 
all experts agree on its utility. As a downstream biomarker, CRP 
provides functional integration of overall upstream cytokine activation. 
With the exception of CRP, however, none of the established and 
emerging novel biomarkers for cardiovascular risk have demonstrated 
additive value to the Framingham risk score, and few have available 
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commercial assays that achieve adequate levels of standardization and 
accuracy for clinical use.  
CSA is an important clinical condition that warrants a good clinical risk 
stratification. The evaluation of LVEF and the extent of atherosclerotic 
coronary disease are essential in this process. However, further 
improvement in the ability to identify individuals at risk to develop 
adverse events is needed.   
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9. OVERVIEW OF THE VALUE OF PREGNANCY 
ASSOCIATED PLASMA PROTEIN-A (PAPP-A) AND 
CARDIOVASCULAR RISK. 
Consuegra-Sánchez L, Fredericks S, Kaski JC. Pregnancy associated plasma protein-
A (PAPP-A) and cardiovascular risk. Atherosclerosis. 2009;203:346-52 (97). 
Consuegra-Sánchez L, Fredericks S, Kaski JC. Pregnancy associated plasma protein 
A: Has this biomarker crossed the boundary from research to clinical practice? Drug 
News Perspect. 2009 (accepted for publication, in press, 98) 
 
Coronary artery disease progression leading to acute coronary syndrome 
(ACS) is a rather unpredictable phenomenon and is often associated to 
atheromatous plaque disruption or endothelial erosion (99). Plaques 
prone to disruption and rapid progression are known as “vulnerable” or 
“complex” plaques (100). Vulnerable plaques progress faster than 
smooth uncomplicated coronary stenoses and lead to the development 
of ACS (101-104) (Fig. 5). Stratification of patients regarding 
cardiovascular risk is largely dependant on relatively crude scores. 
Conventional risk factors, clinical characteristics, electrocardiographic 
findings and serum markers of necrosis are widely used in clinical 
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practice but these are able to single out only a proportion of those 
individuals who are at a high risk of developing acute coronary events. 
Consequently the search for markers that may help to improve risk 
prediction is ongoing. Substantial research efforts have been directed 
towards the identification of vulnerable plaques including the 
development of sophisticated imaging techniques. These methods, 
however, are expensive and some of them invasive thus limiting their 
use in daily practise. The fact that both atherogenesis and CAD 
progression are directly related to inflammatory responses, immune 
activation, and activation of the coagulation and fibrinolytic cascades, 
has generated interest in the potential role of soluble circulating 
“biomarkers” as markers of cardiovascular risk. As abovementioned, 
these serum biomarkers can be an expression of the underlying  
pathogenic  process  and/or  play an active mechanistic role in the 
development and progression of the disease. New markers of CAD 
progression have been identified in recent years, among which, 
circulating levels of pregnancy-associated plasma protein-A (PAPP-A, 
pappalysin-1, EC 3.4.24.79) appear to offer an interesting profile. 
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PAPP-A is a high molecular-mass zinc-binding metalloproteinase 
mainly produced by the placental syncytiotrophoblast during pregnancy, 
but also by fibroblasts, osteoblasts and vascular smooth muscle cells 
(105,106).  
Data from animal and human studies suggest that PAPP-A could play a 
role in the development of atherosclerotic lesions (107-108). In CSA 
patients, high PAPP-A levels correlate with the extent of angiographic 
CAD (109) and the presence of vulnerable coronary artery stenoses 
(110). Moreover, PAPP-A levels are increased in patients with ACS and 
represent a marker of adverse events in ACS patients (table 1) (111-
113).   
 
PAPP-A and stable atherosclerotic disease.  
9.1. Coronary artery disease.  
Previous findings from our group showed that PAPP-A levels correlate 
with the extent of angiographic CAD. Cosin-Sales et al (109) (Fig. 6) 
showed that high levels of PAPP-A identified patients with CSA and 
multivessel disease (6.45 ± 2.58 mIU/L) compared to those with single-
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vessel disease and subjects without CAD, who had lower circulating 
PAPP-A concentrations (5.49 ± 1.54 mIU/L; p < 0.001 and 4.62 ± 1.17 
mIU/L; p < 0.001), respectively. Interestingly these differences 
remained statistically significant after multivariable adjustment.  
Receiver operator characteristic (ROC) curve analysis for the presence 
of CAD in these patients showed that the area under the curve was 0.75 
(95% CI, 0.72-0.78) for PAPP-A and 0.45 (95% CI 0.41-0.49) for high 
sensitivity C-reactive protein (hs-CRP). 
The proform of eosinophil major basic protein (pro-MBP) is an 
endogenous inhibitor of PAPP-A enzymatic activity. PAPP-A 
specifically degrades insulin-like growth factor (IGF) binding proteins 
(114-115). In 396 patients with CSA, Cosin-Sales et al (110) 
demonstrated that the PAPP-A/proMBP ratio was an independent 
predictor of the number of complex stenoses (standardized β = 0.10, p = 
0.026) in a fully adjusted model.  
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9.2. Carotid and peripheral arterial diseases. 
Circulating PAPP-A has been shown to be a marker of echogenicity of 
atheromatous carotid plaques in hyperlipidemic patients (116). In an 
elegant study, Sangiorgi et al (117) reported an association between 
PAPP-A circulating levels, carotid plaque morphology and vascular 
complications. A significant inverse correlation between atheromatous 
plaque cap thickness and PAPP-A levels was found (r = - 0.62, p = 
0.01), whereas a positive correlation was observed between plaque 
inflammation (inflammatory cells/mm2) and PAPP-A levels (r = 0.70, p 
= 0.01).  In this study transcription of PAPP-A messenger ribonucleic 
acid (mRNA) was found to be 2-4 fold higher in symptomatic patients 
i.e those developing a stroke or a transient ischemic attack, compared to 
control individuals and patients without events. PAPP-A has been also 
suggested to be a predictor of ankle-brachial index (r = -0.294, p = 
0.0039) and intima-media wall thickness in common carotid arteries 
(partial coefficient = 0.414, p = 0.002) in type 2 diabetes mellitus with 
hypercholesterolemia (118). Moreover, it has been reported that PAPP-
A may be a marker for the presence of peripheral arterial disease in 
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elderly patients. In these patients it has been suggested that PAPP-A 
concentrations are indicative of the atherosclerotic burden (119). 
 
9.3. Prognostic value in patients with stable atherosclerotic disease 
(table 1). 
In a small study in selected patients with stable angina pectoris, Elesber 
et al (120) showed that PAPP-A, considered as a continuous (log-2 
transformed) variable, correlated with the occurrence of death and ACS 
(adjusted HR = 3.56, 95% CI 1.27-10, p = 0.015), but not with the need 
for revascularization (120).  
 
9.4. PAPP-A and lipids. 
The relationship between PAPP-A levels and statin treatment is 
important in relation to the potential ability of PAPP-A to predict 
patient outcome. Cosin-Sales et al (108) reported that CSA patients 
receiving treatment with statins had lower PAPP-A levels (5.5 ± 1.5 vs. 
6.1 ± 2.4 mIU/L; p = 0.02) than those on no statin treatment. However, 
prospective studies in patients with hypercholesterolemia showed that 
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atorvastatin did not significantly reduce PAPP-A concentration in 
plasma (121).  In myocardial infarction (MI) survivors, Aarsetøy et al 
(122) interestingly reported that patients receiving n-3 fatty acids and 
corn oil for 1 year showed higher levels of circulating PAPP-A. 
 
PAPP-A and the acute coronary syndrome.  
9.5. Diagnostic value. 
Bayes-Genis et al (108) showed that PAPP-A levels were higher in 
patients with ACS (blood samples taken 8.4 ± 3.0 [mean ± standard 
deviation, SD] hours in the MI group, 9.4 ± 3.9 hours in the UA group, 
from last ischemic episode) compared to those with stable angina 
pectoris. They reported a sensitivity for PAPP-A (threshold value of 10 
mIU/L) of 89.2 % and a specificity of 81.3 % in discriminating ACS 
from CSA and control (healthy) subjects.   Interestingly,   they showed   
that   PAPP-A   concentrations correlated with free IGF-1 levels but not 
with markers of myocardial damage such as creatin-kinase MB (CK-
MB) isoenzyme and cardiac troponin (c-Tn). This latter finding, 
however, differs from data reported by Khosravi et al (105) who 
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observed a significant correlation between PAPP-A and troponin levels 
in a subset of troponin-T positive patients with ACS (those with 
troponin T levels up to 2.9 ug/L). These authors, like Bayes-Genis 
previously, also found significantly higher concentrations of PAPP-A in 
patients with ACS (time interval between symptoms onset and blood 
sample not reported) compared to control subjects (105). 
In patients presenting to the emergency department with acute chest 
pain suggestive of ACS (time interval between symptoms onset and 
blood sample not reported), Elesber et al (123) reported that PAPP-A 
levels were predictive of a final diagnosis of ACS in a multivariable 
model (Odds ratio [OR] = 2.093; 95% CI 1.037-4.224; p= 0.039). 
Laterza et al (124) recruited 346 patients with symptoms suggestive of 
ACS (blood samples taken 9 hours on average after symptoms onset), 
33 of whom suffered adverse events (3 deaths, 14 acute MI, and 23 
revascularization procedures) over a 30 day follow-up period. They 
reported that on analysis of the ROC curves, cTnT was a better 
predictor of 30-day events than PAPP-A. Our group recently (125) 
evaluated the value of PAPP-A, NT-proBNP and CRP in combination 
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with clinical data and exercise testing for the evaluation of 422 patients 
with chest pain without ST-segment deviation or troponin elevation. By 
univariate unadjusted ROC analysis, PAPP-A showed a border-line 
significant association with the occurrence of all-cause death or 
myocardial infarction (p = 0.07) and adverse cardiac events (all-cause 
death, myocardial infarction or coronary revascularization; p = 0.04) 
during a 60 weeks (median) follow-up. However -in a Cox 
multivariable model- PAPP-A was not an independent predictor of 
either study endpoints. Contrary to the findings of previous 
investigations, a small study by Dominguez-Rodriguez et al (126) in 
patients with ST-elevation ACS found no differences in PAPP-A 
concentrations in patients (n = 80) compared to control subjects (n = 
80), in samples taken (mean ± SD) 6.3 ± 2.8 hours after the onset of 
symptoms. The small sample, absence of a sample-size calculation and 
the case-control nature of the study might have accounted for the 
probable type 2 error. Thus, PAPP-A levels –when determined within 
the first twelve hours- may identify patients in the process of plaque 
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instability, when it might be most beneficial to receive intensive 
treatment for the ACS. 
 
9.6. Kinetics of PAPP-A (98). 
Qin et al (113) reported that increases in PAPP-A levels above the 
reference range are highly variable in ACS patients, in that they may be 
present early at 2 hours or late at 30 hours after onset of chest pain. 
Lund et al (127) suggested that PAPP-A release patterns in ST-segment 
elevation ACS might be influenced by the occurrence and timing of 
reperfusion.  
Recently, Iversen et al (128) published results concerning the releasing 
pattern of PAPP-A after the occurrence of an ST- elevation ACS in 354 
patients. For this study, that in turn was specifically designed with the 
purpose of assessing the PAPP-A release, samples were taken at 
admission (median time from symptoms onset to admission 7.5 hours) 
and every 6 to 8 hours until biomarkers of necrosis were consistently 
decreasing. The peak concentrations of circulating PAPP-A (Fig. 7) 
were found 5.77 hours ( 95% CI 4.95-6.58) after the onset of symptoms 
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and significantly earlier than cTnT or CKMB peaks. In patients who 
undergo percutaneous coronary intervention (PCI), a single substantial 
PAPP-A increase shortly after the procedure followed by a return to 
normal levels (128). This finding is in accordance with other studies 
showing a similar pattern (129). 
In patients with a non-ST segment elevation acute MI, it has been 
reported that PAPP-A concentrations significantly correlate with ST-
depression, multivessel disease, typical angina at presentation and other 
“high risk” conditions (130).   
 
9.7. Prognostic value in ACS. (table 1) Negative troponin patients. In a 
cohort of 200 patients with suspected ACS and negative cardiac 
troponin, Lund et al (111) interestingly reported that highest (assessed 
within the first 24 hours after admission) PAPP-A levels (> 2.9 mIU/L) 
were independently associated with an adverse outcome at 6 months 
follow-up (i.e. cardiac events and need for revascularization). Moreover, 
a single admission PAPP-A level > 2.9 mIU/L also showed a significant 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 63
association with the study endpoint (Relative risk = 2.3, 95 % CI 1.1-5, 
p = 0.003). 
Positive troponin patients. In patients with ACS (comprising 205 
patients with acute MI and 342 with unstable angina) and documented 
CAD recruited in the large CAPTURE (Chimeric c7E3 AntiPlatelet 
Therapy in Unstable angina REfractory to standard treatment trial) 
study (112), Heeschen et al showed that patients with higher PAPP-A 
values (>12.6 mIU/L) were at increased risk of death or MI during the 6 
month follow-up (multivariate OR = 2.44, 95% CI 1.43-4.15, p = 
0.001). Importantly this independent association of PAPP-A with 
adverse clinical outcome was also observed in patients with negative 
cTnT values (multivariate OR = 2.72, 95% CI 1.25-5.89, p = 0.009). Of 
interest a significant interaction between PAPP-A and the anti-
inflammatory cytokine interleukin (IL) 10 was found whereby the 
association of PAPP-A with the composite endpoint (death and nonfatal 
MI) was limited to patients with circulating IL-10 concentrations <3.5 
ng/mL. The authors therefore concluded that the balance between pro-
inflammatory and anti-inflammatory cytokines determines the course of 
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the disease in those patients with IL-10 concentrations <3.5 ng/mL, who 
in turn, had a higher rate of revascularization procedures during follow-
up. In a small cohort of patients with ST-segment elevation acute MI (n 
= 62), Lund et al (127) found that PAPP-A > 10 mIU/L was a 
significant predictor of 12-month risk of cardiovascular death or non-
fatal MI.   
 
9.8. PAPP-A and plaque instability: Cause or consequence? 
Figure 8 summarizes the evidences supporting the role of PAPP-A in 
cardiovascular disease. 
It has been suggested that PAPP-A is implicated in repair mechanisms 
directly contributing to plaque stabilization, thus having a protective 
role (131-132). In contrast PAPP-A may have a more deleterious role by 
breaking down extra-cellular matrix via its metalloproteinase character. 
These paradoxical functions can only be understood through 
understanding the pathophysiology. During pregnancy PAPP-A is 
synthesized in the trophoblastic cells of the placenta and released to the 
circulation. Although the role of PAPP-A in pregnancy is still not well 
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understood, it seems to play a role in the placental development (133). 
PAPP-A produced during pregnancy, however, differs from that present 
in eroded and ruptured atherosclerotic plaques in that the latter is not 
complexed with its endogenous inhibitor, the pro-MBP. This “free” 
PAPP-A shows metalloproteolytic activity directed towards insulin-like 
growth factor binding protein 4 and 5, and leads to the release of bound 
IGF (114,115). Given its proteolytic potential and the associations 
found between high PAPP-A concentrations and complex 
atherosclerotic plaques and impaired clinical outcome, it may be 
speculated that PAPP-A may contribute to the degradation of the plaque 
extracellular matrix. However, beyond the degradation of IGF-1 binding 
proteins, no other proteolytic action has been so far demonstrated for 
PAPP-A (134).  Furthermore, recent data suggest that PAPP-A is not 
synthesized in macrophages but rather binds to the membrane of these 
cells, with only 50 % being internalized (135). It has been shown that 
whilst membrane-bound  PAPP-A has proteolytic activity,  internalized 
PAPP-A has little or no protease activity (135). In vitro studies showed 
that IGF may induce macrophage activation, chemotaxis, LDL-
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cholesterol uptake by macrophages and release of proinflammatory 
cytokines, thus suggesting a pro-atherogenic action of IGF-1 (136,137). 
However more recent clinical and experimental evidences suggest that 
IGF-1 may protect against ischaemic heart disease preserving 
endothelial function, promoting plaque stability and exerting anti-
inflammatory and anti-oxidant effects (131, 132). If IGF is 
“cardioprotective”, it should -at least theoretically- follow that elevated 
PAPP-A levels should also be cardioprotective (134). The question thus 
emerges as to whether PAPP-A causes plaque instability or plaque 
instability and myocardial ischaemia are stimuli for PAPP-A secretion, 
which may contribute to plaque stability and healing. It has been 
suggested that PAPP-A suppresses inflammation (138). The relatively 
poor correlation between PAPP-A and markers of necrosis in ACS 
patients, suggests that increased PAPP-A levels cannot be attributed to 
myocardial necrosis (139). Recently Park at al examined the association 
of four single nucleotide polymorphisms within the PAPP-A gene in 
relation to acute MI. In a case-control study containing 170 acute MI 
patients and 170 age-matched controls the authors found the PAPP-A 
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IVS6+95 C allele to be an independent predictor of increased risk of 
acute MI (heterozygote- OR=1.89 [95% CI: 1.14-3.16]; p=0.015) (140). 
This polymorphism is located in an intron that is believed to be closely 
related with other unknown gene variants in the exon portion. The 
functional significance (i.e. circulating PAPP-A levels, enzymatic 
activity) of this and other PAPP-A polymorphism is not known so far 
(140). These data taken together indicate that more work is required to 
define the true role of PAPP-A in plaque instability; the reverse 
causality hypothesis requires further investigation. 
 
9.9. Biochemical considerations.  
The identification of PAPP-A in atherosclerotic plaques by 
immunohistochemical techniques   (108,117,141)   has   been   central   
in   forging   a   link between PAPP-A and cardiovascular disease. 
Unfortunately, the use of different assays by different researchers has 
lead to some controversy regarding the importance of this potential 
marker of plaque instability (26,142,143). Moreover there has been 
uncertainty as to which is the most appropriate molecular form of the 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 68 
PAPP-A protein to measure (142).  To a substantial extent these 
disparities relate to the method of quantitative analysis. Current research 
has been based on immunoassay systems which depend on two 
antibodies (a capture and a detection antibody) used to recognise 
specific epitopes on the PAPP-A antigen (Fig. 9). In circulation PAPP-
A typically exists as a disulfide-bound heterotetrameric complex with 
the proMBP (144), present at low concentrations in non-ACS 
individuals and at higher concentrations in pregnant women. However, 
the PAPP-A immunoassays extensively used for cardiovascular research 
have been based mainly on assays designed to recognise the 
PAPP-A/proMPB complexed form of the molecule (108,111,112).  
Historically PAPP-A assays used for diagnostics purposes in pregnancy, 
were first used to identify foetal Down’s syndrome (145), and were then 
adapted for use in other disease areas. Qin et al reported that, 
theoretically, the free form of PAPP-A (disassociated from proMBP) is 
the only relevant molecular form in patients with ACS (142,146), as it is 
released from unstable atherosclerotic plaques. Recently two high 
sensitive assays have become commercially available  for  the detection 
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of PAPP-A: one assay manufactured by DRG Co. (Germany) failed to 
detect any difference in serum PAPP-A concentrations between healthy 
controls (n = 80) and patients with ST-segment elevation myocardial 
infarction (n = 80) (126), whilst the other manufactured by Diagnostic 
System Laboratories (DSL, Webster, TX) has been used in several 
positive investigations of vascular disease (119,123,124,147). 
Although it has been suggested that the most appropriate method of 
analysis would be based on the specific detection of the free PAPP-A 
molecule (142), several of the early reports on ACS and serum PAPP-A 
concentrations were performed using an in-house assay which employed 
a polyclonal capture antibody, rather than the more specific monoclonal 
pairs used in commercial assays (108-110,120).  
The direct measurement of free PAPP-A would be the ideal method 
(142). One approach has been to perform two assays in conjunction, one 
that specifically detects the PAPP-A/proMBP  complex   and   one   that   
detects total PAPP-A. The amount of free PAPP-A can then be 
calculated as the difference in concentration determined by the two 
assays (Fig. 9). This method has been presented in a report by Wittfooth 
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et al (148) who described two point-of-care assays performed on an 
auto-analyser; All-In-One! Immunoanalyzer (Aio!; Innotrac 
Diagnostics). Another approach -that has been successfully employed 
for other metalloproteinases- may be to analyse the enzymatic activity 
of PAPP-A that is attributed to free-PAPP-A.Total PAPP-A assays have 
proved their worth in cardiovascular research in the clinical setting. 
However, the development of assays for PAPP-A activity and free 
PAPP-A, have the potential to be useful tools for investigating the 
pathophysiology of PAPP-A at the molecular and cellular level.  
 
9.10. Statistical considerations.  
Despite of the existence of encouraging literature reporting 
“independent associations” between PAPP-A (and other biomarkers) 
and events during follow-up in painstakingly adjusted models, its 
clinical applicability is still poor. Besides the biochemical concern with 
PAPP-A assays, one of the aspects that might -at least partially- account 
for this situation is the controversy regarding statistical methods for the 
evaluation of “clinical impact” of a biomarker in a particular scenario. 
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Pepe et al (149) indicated that the global evaluation of a biomarker 
should comprise not only the assessment of independent associations 
but also the analysis of the “incremental value or predictive ability” (so-
called “discrimination”) by mean of the study of the area under the ROC 
curve or c statistic. This means that a biomarker should increase 
sensitivity and /or specificity -to identify individuals at higher risk- as 
compared to a standard risk score to improve the C-statistic.  However, 
this approach has pitfalls since standard methods do not exist for 
deriving ROC curves for time-to-event data. Cook et al (150) recently 
reported that the C statistic might not be optimal in assessing models 
that predict future risk and that the solely reliance on this parameter may 
be insufficient. Several traditional and emerging risk factors may have 
little effect on the C statistic but substantially shift future cardiovascular 
risk for an individual patient. In this regard many accepted risk factors 
(i.e. hypertension) have only marginal impact on C statistic but are 
clinically relevant as stratification variables (150,151). Model 
calibration is a measure of how well the predicted risk fits with the real 
(observed) risk and is becoming important as an indicator of the 
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accuracy of a model (151). Moreover it has been suggested that a useful 
method to evaluate a biomarker may consist in the evaluation of the 
number of subjects that eventually would be   reclassified   (in terms of 
risk category) with the use of a biomarker compared to a classical model 
of risk prediction (152). To date, beyond “independent associations”, no 
studies have been reported that demonstrate a significant improvement 
in discrimination, calibration or reclassification ability with the use of 
PAPP-A.  
 
9.11. General Conclusions.  
There is evidence suggesting that PAPP-A could play a role in the 
development of atherosclerotic lesions (Fig. 8) and may represent a 
marker of atheromatous plaque instability and extent of cardiovascular 
disease. Studies have shown that PAPP-A levels are increased in 
patients with ACS and represent a marker of adverse events in this 
group (table 1). Whether PAPP-A causes vascular wall damage or –on 
the contrary- has a protective vascular effect, as suggested by some 
authors, needs to be further investigated in ad hoc studies. Taken the 
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available data together PAPP-A appears to provide complementary 
information to that provided by markers of myocardial necrosis. Assays 
measuring total PAPP-A have proved their worth in clinical research. 
However, the development of assays to measure PAPP-A activity and 
free PAPP-A levels, may offer potential for the investigation of the true 
role of PAPP-A in the pathophysiology of cardiovascular disease.  
Studies are necessary also at the molecular and cellular levels to better 
characterize this protein and its changes in the disease process.  
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10. ORIGINAL RESEARCH.  
Consuegra-Sanchez L, Petrovic I, Cosin-Sales J, Holt DW, Christiansen M, Kaski JC. 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels in Patients with 
Chronic Stable Angina Pectoris. Clin Chim Acta 2008; 391:18-23 (153). 
 
10.1. Hypothesis. Rationale and objectives.  
The concept that inflammation is pivotal in atherothrombosis has 
boosted sustained efforts to identify biomarkers that might improve 
cardiovascular risk prediction. PAPP-A has become a promising 
biomarker in cardiovascular medicine (105-125, 127-140) in recent 
years. However, in CSA patients, data regarding the value of PAPP-A 
as a risk marker of adverse events are sparse (120). Moreover, in 
addition to statistical associations, no studies -to date- have evaluated 
the contribution of PAPP-A in the ability to identify individuals at risk –
so-called discrimination- or the precision in terms of risk –calibration-.  
The a priori objectives of this study were: 
1. We primarily sought to assess whether PAPP-A levels -
evaluated during routine angiography- are a marker of all-cause 
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mortality during long term follow-up in a non-selected 
population of CSA patients.  
2. Beyond the “statistical association”, the study was also aimed at 
assessing whether the determination of this biomarker might 
complement and improve the “discrimination” and “calibration”, 
when compared to the traditional (clinical) model. 
3. As third objective, we evaluated whether the determination of 
pro-MBP levels and the ratio PAPP-A/pro-MBP is a marker of 
all-cause mortality in a subgroup of the total sample. 
4. Finally, we aimed at assessing the clinical independent 
predictors of adverse outcome in CSA patients. 
We consequently hypothesized that (1) the determination of PAPP-A -
as a readily available marker obtained by mean of a simple blood test- 
might be associated with an adverse outcome in CSA patients (2) 
PAPP-A might improve the sensitivity and/or specificity in the 
identification of individuals at risk, compared to that obtained with 
traditional or clinical risk factors and (3) PAPP-A might improve the 
precision in terms of risk estimation, compared to a traditional model. 
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10.2. METHODS.  
10.2.1. Patients. Inclusion and exclusion criteria. 
This was a prospective study in 663 consecutive patients with diagnosis 
of CSA (recruited from 1st, November 1994 to 15th, August 1997) 
undergoing routine diagnostic coronary angiography in St. George’s 
Hospital, London.  
CSA was defined as typical chest pain during exercise, relieved by rest 
and/or sublingual nitrates, with symptoms unchanged for at least 6 
months before study entry.  
The following variables were collected at study entry: age, gender, body 
mass index, systolic and diastolic blood pressure, Canadian 
Cardiovascular Society functional class, family history of CAD, 
smoking, diabetes mellitus, hyperlipidemia, hypertension, previous 
myocardial infarction, prior percutaneous coronary angioplasty, total 
cholesterol, HDL-cholesterol, LDL-cholesterol, creatinine, triglycerides, 
C-reactive protein, number of diseased vessels, Sullivan’s extension 
score, LVEF, revascularization at index hospitalisation, treatment at 
discharge (aspirin, betablocker, lipid lowering drugs, angiotensin-
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converting enzyme inhibitors, calcium channel blockers) and all-cause 
deaths. 
We did not include patients with any of the following: <12 weeks ACS, 
life threatening arrhythmias, acute or chronic liver disease, renal failure, 
and chronic inflammatory and/or immunological conditions. Follow-up 
information on mortality was obtained by a periodic review of the 
patients’ clinical notes, postal questionnaires sent to the patients’ 
general practitioners, and telephone contact with patients and/or their 
families.   
 
10.2.2. Study endpoint. Follow-up. Variables’ definitions. 
The primary study endpoint was all-cause mortality. We limited our 
analysis to all cause mortality as this information could be obtained 
accurately during the long term follow-up. 
Follow-up data were available in 624 patients (94 %). Follow-up 
information on mortality was obtained –as abovementioned- by a 
periodic review of the patients’ clinical notes, postal questionnaires sent 
to the patients’ general practitioners, and telephone contact with patients 
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and/or their families. The study protocol, which is in accordance with 
the current revision of the Helsinki Declaration, was approved by the 
Local Research Ethics Committee, and all patients gave written 
informed consent before study entry.  
Arterial hypertension was defined in the presence of a systolic blood 
pressure of ≥140mmHg and/or diastolic blood pressure of ≥90mmHg 
measured on at least two separate occasions. Hyperlipidemia was 
defined as a documented total cholesterol value >5.4 mmol/L. Smokers 
were defined as those currently smoking tobacco. Patients were 
considered to have diabetes mellitus if they were receiving active 
treatment with insulin or oral hypoglycemic agents. For patients on 
dietary treatment alone, documentation of abnormal fasting blood 
glucose or glucose tolerance tests according to World Health 
Organization criteria were required for the diagnosis of diabetes. 
 
10.2.3. Angiographic analyses. 
As described previously (109, 110), during coronary angiography 
(Judkins technique) images of the coronary tree were obtained in routine 
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standardized projections (Philips Integris 3000 system, Philips, 
Holland).  In every coronary angiogram, we assessed the number of 
major coronary arteries showing ≥ 75 % lumen diameter reduction 
(“vessel score”) and  quantified  the  extent  of  angiographic  coronary  
atherosclerosis using the Sullivan scoring system (154). The Sullivan 
“extension score” refers to the proportion of the coronary tree showing 
angiographically detectable atheroma. The observed proportion of 
atheroma in each vessel is multiplied by a factor that varies according to 
the artery involved: left main stem, 5; left anterior descending coronary 
artery, 20; main diagonal branch, 10; first septal perforator, 5; left 
circumflex artery, 20; obtuse marginal and posterolateral vessels, 10; 
right coronary artery, 20; and main posterior descending branch, 10. 
When the major lateral wall branch was a large obtuse marginal or 
intermediate, this was given a factor of 20, and left circumflex artery, a 
factor of 10. When a vessel was occluded and the distal bed was not 
fully visualized by collateral flow, the proportion of vessel not 
visualized was given the mean extent score of the remaining vessels. 
The scores for each vessel or branch were added to give a total score out 
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of 100, representing the percentage of the coronary lumenal surface 
involved by atheroma. Interobserver agreement (calculated as intraclass 
correlation coefficient) regarding extension score in the present study 
was 0.97.    
 
10.2.4. Biochemical measurements. 
Fasting blood samples were obtained from every patient at the time of 
coronary angiography. Blood was drawn and centrifuged immediately 
and the serum was then aliquoted and stored at -80ºC. PAPP-A levels 
were determined using a biotin-tyramide-amplified enzyme 
immunoassay with a limit of detection of 0.03 mIU/L. Intra-assay and 
inter-assay coefficients of variation were 10 and 15%, respectively. 
PAPP-A polyclonal antibodies were used for capture and a combination 
of monoclonal antibodies were used for detection. The assay detects and 
quantifies total PAPP-A (free PAPP-A plus the PAPP-A/proMBP 
complex) and was calibrated against the World Health Organization’s 
International Reference Standard 78/610.  
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CRP measurements were performed on the COBAS Integra (Roche 
Diagnostics Limited, Lewes, East Sussex, UK) using the CRP-Latex 
assay in both the high sensitivity application (analytical range 0.2-
12mg/L) and the normal application (analytical range 2-160 mg/L). 
Analytical precision of the high-sensitivity CRP-latex assay was 7.6% at 
a level of 1.02 mg/L, 3.3% at 1.79 mg/L, and 1.3% at a level of 4.36 
mg/L.  Samples outside the analytical range of the high sensitivity CRP-
Latex assay were analysed by the CRP-Latex in the normal application. 
Analytical precision of the normal CRP-latex assay was 2.4% at a level 
of 29.5 mg/L and 1.3% at a level of 113 mg/L.  LVEF was assessed in 
563 patients (79 %). 
Total pro-MBP levels were assessed in 385 patients with an 
immunoassay developed at the Statens Serum Institute, Copenhagen. 
Within the calibrator range used, the interassay variation coefficient was 
< 5% (155). 
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10.2.5. Statistical analysis. 
In this study involving 663 patients, the statistical power was 95 % to 
detect a difference of 12 percent units (4th quartile vs 1st quartile) 
assuming an expected event rate of 8 % in subjects in the first PAPP-A 
quartile -based on previous pilot work from our group- and a type I 
error of 0.05. Differences in variables between groups were assessed 
using the Chi-Square test or Fisher’s exact test for categorical variables 
and Student t test or the Mann-Whitney test for continuous variables. 
The Spearman two way test was used to assess the relation between two 
quantitative variables with non-normal distribution. Long-term 
mortality was analyzed by the Kaplan-Meier method, and differences 
were compared with log-rank (Cox-Mantel) test. We tested the 
proportional hazard assumption with visual plots. Variables included in 
the multivariable analysis (covariates) were those that showed a 
significant association both with the study endpoint and higher values of 
PAPP-A (Group 2 = PAPP-A > 4.6 mIU/L) on univariate analysis (p < 
.05), variables that showed a trend (p < .10) towards an association, and 
variables considered to be of clinical relevance (gender, type 2 diabetes 
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mellitus, revascularization at index hospitalization and CRP). In patients 
in whom ejection fraction was not measured, the value was imputed 
with the sample median to include all subjects in the model. The 
backward stepwise likelihood ratio was used to derive the final model 
for which significance levels of 0.1 and 0.05 were chosen to exclude 
and include terms, respectively. The HR and their 95% CI were 
calculated with a Cox multivariable regression model and 
bootstrapping. χ2 statistic analysis  was  performed to assess  the  
importance of  each  covariate in the final multivariable model. We used 
a multivariate fractional polynomial approach to test the probability of a 
threshold effect. Calibration of the multivariable model with and 
without the incorporation of the biomarker PAPP-A was assessed with 
Hosmer-Lemeshow test. Logarithmic transformation was performed to 
normalize the distribution of CRP. The Harrell’s C-statistic (equivalent 
to the area under the Receiver Operating Characteristic curve) was 
calculated for the model. Tests were considered to be statistically 
significant if p < 0.05. Statistical analyses were performed with SPSS 
13.0 (SPSS Inc., Chicago, IL).  
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10.3. RESULTS. 
10.3.1. Baseline Characteristics. 
Six-hundred and sixty-three CSA patients (mean age 62.9 ± 9.7 years, 
494 (74.5 %) male) were recruited.  Patients were followed for a median 
of 8.8 years (interquartile range 3 - 10.6 years). Table 2 shows 
demographic, clinical, angiographic and biochemical data of all patients 
included in the study. PAPP-A levels were a priori stratified in quartiles 
(1st quartile ≤ 4.6 mIU/L; 2nd quartile 4.6-5.6 mIU/L; 3rd quartile 5.6-6.8 
mIU/L; 4th quartile ≥ 6.8 mIU/L). Analysis of PAPP-A quartiles in 
relation to survival with Kaplan-Meier curves (Fig. 10) showed little, if 
any, difference in the cumulative mortality rate between patients in 
quartiles 2, 3 and 4 suggesting  the presence  of  a  threshold effect 
between patients in the 1st quartile and those in the remaining quartiles 
(log rank = 9.39, p = 0.002). Consequently, patients were subdivided 
into two groups according to the 25th percentile, i.e. Group 1 comprised 
patients in the 1st PAPP-A quartile, and Group 2, patients belonging to 
the remaining 3 quartiles.  
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Median (25th and 75th percentiles) PAPP-A was 5.6 mIU/L (4.6-6.8).  
PAPP-A levels ranged from 1.2 mIU/L to 17.20 mIU/L. Median CRP 
concentration (25th and 75th percentiles) was 2.3 mg/L (1.1-4.62) and 
CRP levels ranged from 1.1 mg/L to 4.62 mg/L. Median (25th and 75th 
percentiles) pro-MBP was 1938 mIU/L (1484-2516). Pro-MBP levels 
ranged from 484 mIU/L to 8696 mIU/L. CRP levels did not correlate 
with PAPP-A or pro-MBP levels (p = 0.66 and 0.38, respectively). 
Circulating PAPP-A levels, however, correlated significantly with pro-
MBP levels (r = 0.485, p < 0.001). Table 2 shows the univariable 
comparison between group 1 and 2. Compared  to  patients  in   group 1,  
group  2  patients   were  older   (p < 0.01),  with  a predominance of 
males  (p < 0.01). Moreover ,  more  patients  in  group 2  had  systemic 
hypertension (p = 0.05), a higher number of coronary arteries with ≥ 75 
% stenosis (vessel score) (p < 0.01), a higher Sullivan extension score (p 
< 0.01), higher creatinine levels (p < 0.01) and lower LVEF (p < 0.01).  
Importantly, cumulative all-cause mortality was lower (8.5 %) in 
patients in the 1st PAPP-A quartile compared to those in the 2nd, 3rd and 
4th quartiles (20 %)  (p < 0.001). This suggested the presence of a 
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threshold effect, which we specifically tested using a multivariate 
fractional polynomial model that identified a PAPP-A threshold at 4.8 
mIU/L (Percentile 30)(Fig. 11).  
 
10.3.2. Events during follow-up and univariate analysis. 
During follow-up, 106 patients (16 %) died. On univariate analysis age 
(p < 0.01), Canadian Cardiovascular Society Functional Class (p = 
0.04), smoking (p = 0.02), systemic hypertension (p = 0.02), previous 
MI (p = 0.01), creatinine levels (p < 0.01), CRP (p < 0.01), PAPP-A (p 
< 0.01), vessel score (p < 0.01), Sullivan extension score (p < 0.01) and 
LVEF (p < 0.01) correlated with the occurrence of the endpoint (Table 
3).   
Coronary revascularization performed during index hospitalization, 
however, was associated with a reduction in the occurrence of the study 
endpoint (p = 0.05). 
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10.3.3. Multivariable analysis. 
We further tested the proportional hazard assumption with visual plots 
and appeared valid for all analysis (Fig. 12). 
An increased PAPP-A concentration > 4.8 mIU/L was independently 
associated with all-cause mortality (HR 1.953, 95% CI 1.135-3.36, p = 
0.016), after adjusting for age, gender,  hypertension,  hyperlipidaemia,  
creatinine,  vessel score,  Sullivan extension score, LVEF, type 2 
diabetes mellitus, revascularization at index hospitalization and CRP. 
No significant interaction was found for gender regarding the 
association of circulating PAPP-A levels and the study endpoint (p for 
interaction = 0.79). 
PAPP-A levels (> 4.8 mIU/L) remained an independent predictor of the 
study endpoint (HR 1.911, 95% CI 1.112-3.285, p = 0.019) even after 
entering treatment at discharge (aspirin, beta-blockers, lipid-lowering 
drugs and angiotensin-converter enzyme inhibitors) in addition to the 
full model.  
Of importance χ2 analysis showed that PAPP-A > 4.8 mIU/L (χ2 = 
6.683) was the strongest predictor after age (χ2 = 17.052) and CRP (χ2 = 
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14.066) followed by revascularization at index hospitalization (χ2 = 
5.099), vessel score (χ2 = 5.059), creatinine (χ2 = 4.141) and LVEF (χ2 = 
3.181) and in the final model.  
In our study the independent predictors of all-cause mortality are shown 
in table 4. Beyond PAPP-A, age (years) (HR = 1.051, p < 0.001), 
revascularization at index hospitalization (HR = 0.513, p = 0.038), 
vessel score (HR = 1.290, p = 0.026), creatinine (µmol/L) (HR = 1.009, 
p = 0.010) and CRP (mg/L) (HR = 1.414, p < 0.001) were independent 
predictors of all-cause death. LVEF (percent units) was borderline 
significant (HR = 0.986, p = 0.065). 
  
10.3.4. Calibration. Discrimination. Bootstrapping. Additive value. 
Model calibration -as assessed with Hosmer-Lemeshow test- did not 
either significantly change with and without the inclusion of PAPP-A to 
the full clinical model (Table 5). 
The analysis of the Receiver Operating Characteristic Curve (Fig. 13A) 
of PAPP-A in relation to survival revealed that the optimal PAPP-A cut-
point (4.8 mIU/L) showed a high sensitivity (0.84) albeit low specificity 
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(0.33). We also compared two multivariate models, with and without 
the inclusion of PAPP-A; the Harrell’s C-index before incorporation of 
PAPP-A (complete model included age, gender, hypertension, 
hyperlipidaemia,  creatinine,   vessel score,    Sullivan  extension score,   
LVEF, type 2 diabetes mellitus, revascularization at index 
hospitalization and CRP) was 0.74, which increased to 0.75 after 
including PAPP-A in the model (Fig. 13B). To remain on the cautious 
side we further applied a bootstrapping method to estimate standard 
errors and confidence intervals till 4000 replications. This method 
interestingly showed that the association between PAPP-A levels and 
all-cause death was consistently significant till 100 replications and 
borderline-significant afterwards (see table 6). 
We also explored to what extent the biomarker PAPP-A might add to 
the predictive value of CRP in patients presenting with CSA (Fig. 14). 
The test for interaction was positive (interaction p value = 0.01). 
Interestingly when CRP levels were below the median, the contribution 
of PAPP-A levels was neutral; however, when CRP levels were 
elevated above the median, those patients with higher PAPP-A levels 
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(above the median) represented an even higher risk subgroup of adverse 
events. These individuals revealed a hazard ratio of 2.09 (95% CI: 1.08–
4.04) (Fig. 14) compared to those with CRP and PAPP-A below the 
median (reference category, HR = 1). 
 
10.3.5. Prognostic value of Pro-MBP and PAPP-A/pro-MBP ratio. 
Pro-MBP levels (mIU/L), considered as a continuous variable, did not 
differ significantly in survivors, compared with patients who died 
during follow-up (1896 [1466-2481] vs 1982 [1447-2811], p = 0.45). A 
trend towards a higher PAPP-A/pro-MBP ratio was observed in patients 
who died compared to survivors (2.92 [2.24-3.69] x 10-3 vs 2.80 [2.24-
3.51] x 10-3 vs, p = 0.54).  
Analysis of pro-MBP quartiles and PAPP-A/proMBP ratio quartiles 
(Figs. 15, panels A & B) did not show difference in the cumulative 
mortality rate between patients in the different quartiles (log rank = 
0.99, p = 0.8 and log rank = 2.18, p = 0.55, respectively). 
                                
 
                                
 
Prognostic Value of Circulating Pregnancy-Associated Plasma Protein–A (PAPP-A) 
 
and Proform of Eosinophil Major Basic Protein (pro-MBP) Levels 
 
in Patients with Chronic Stable Angina Pectoris 
 91
10.4. DISCUSSION. 
Our study showed an independent association between circulating 
PAPP-A levels and the occurrence of all-cause death in CSA patients 
during long term follow up. Our findings in a larger group of patients 
undergoing diagnostic coronary arteriography confirm and expand 
recent observations by Elesber et al (120) in a small group of selected 
patients with CSA. The present study was not aimed at dissecting the 
mechanisms whereby PAPP-A is a predictor of mortality. However, 
findings in previous studies from our group that PAPP-A levels 
correlate with the extent and severity of angiographic coronary artery 
disease (109) and with the occurrence of angiographically complex 
stenoses (110) in stable angina patients, provide  clues  in  this regard.  
The metalloproteolytic activity of PAPP-A is directed towards insulin-
like growth factor binding protein 4 and 5 (IGFBP 4-5), leading to the 
release of insulin growth factor-1 (IGF-1) (114). In vitro studies have 
shown that IGF-1 can induce macrophage activation, LDL-cholesterol 
uptake and the release of proinflammatory cytokines by macrophages 
(137) thus suggesting a pro-atherogenic action of IGF-1. However more 
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recent studies suggest that IGF-1 may be protective against ischaemic 
heart disease by preserving endothelial function, promoting plaque 
stability and exerting anti-inflammatory/anti-oxidant effects (134,138). 
Pro-MBP functions as an inhibitor of the proteolytic activity of PAPP-A 
and, as such, might potentially affect IGF-1 actions (156). We have 
shown previously that PAPP-A/pro-MBP ratio and PAPP-A levels are 
both higher in CSA patients with complex coronary lesions (110). 
Complex stenoses have prognostic importance in CSA patients, as these 
lesions progress faster than smooth coronary stenoses and lead to ACS 
(103). In the present study, patients who died had higher PAPP-A levels 
than those who survived and the prognostic information provided by 
PAPP-A was independent from that provided by CRP.  However, the 
PAPP-A/pro-MBP ratio was not significantly different in patients who 
died during follow up compared to survivors (adjusted HR = 1.011, 95 
% CI 0.82 – 1.247, p = 0.91). The lack of prognostic value of PAPP-
A/pro-MBP was likely due low statistical power given the relatively 
small number of patients in this subgroup. Moreover, the pro-MBP 
assay used in the present study was aimed at measuring total pro-MBP 
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i.e. free pro-MBP and pro-MBP complexed with angiotensinogen, 
complement C3dg and PAPP-A (155). This might have diluted the 
potential value of pro-MBP and PAPP-A/pro-MBP ratio as markers of 
all-cause mortality. Also, the use of one time point measurement, as 
opposed to   an  average  value  over  a  period  of  time,  to  predict  
mortality over the long-term follow-up might have underestimated our 
results due to the regression dilution phenomenon (157). Further studies 
at a molecular level are necessary to elucidate the relationship between 
pro-MBP and atherogenesis (155). 
In our study, contrary to Elesber et al’s findings (120), PAPP-A 
concentration entered in the statistical model as a continuous variable 
(log base-e transformed) was not a significant predictor of all-cause 
mortality (adjusted HR 1.634, 95% CI 0.818-3.264, p = 0.164). Elesber 
et al assessed a relatively small (n = 103) and highly selected patient 
group, excluded patients with <50% coronary stenoses, and included a 
substantial number (39%) of patients without angina with a positive 
stress test result. These differences may have accounted for the different 
findings in our study. We do not have an explanation for the puzzling 
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finding of a PAPP-A threshold, so further investigation for this 
phenomenon is required. 
Of importance, whilst increased PAPP-A levels have been shown to be 
a marker of atherogenesis and coronary artery disease activity, it has 
been suggested that the circulating form of PAPP-A that accounts for 
the increased concentration observed in ACS patients differs from that 
seen in pregnant women, or normal non-pregnant individuals (142). In 
fact, ACS-related PAPP-A is believed to originate from ruptured 
atherosclerotic plaques and is not complexed with pro-MBP (free 
PAPP-A) (142).  Non-complexed PAPP-A retains its proteolytic 
activity. In a recent study, Wittfooth et al showed that circulating PAPP-
A in non-ACS individuals consisted predominantly of complexed 
PAPP-A/pro-MBP, and free PAPP-A concentrations were negligible 
(148). It is therefore likely that free PAPP-A may be a more specific 
marker of risk of adverse events than complexed or “total” PAPP-A, as 
suggested by Qin et al (142), but this needs to be formally assessed in 
ad hoc studies.  
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In our study we found that CRP was both independently associated and 
the second most powerful predictor of all-cause death in CSA patients. 
This finding is in agreement with previous observations of our group 
and others. Arroyo-Espliguero [158] recently observed that hs-CRP (OR 
2.2 [1.3–3.6] CI 95%; P = 0.002) was an independent predictor of 
NYHA functional classes III–IV irrespective of LVEF and angiographic 
severity of CAD. Authors identified a CRP value of 3.2 mg/L that 
showed a moderate-to-high sensitivity (72%) and specificity (75%), but 
excellent negative predictive value (96%) for detecting an impaired 
functional class. More importantly, our group [159-160] reported that 
CRP levels predict cardiac adverse events in patients with stable CAD, 
regardless of the presence or absence of flow limiting coronary lesions 
and revascularization.  In the large prospective study by Zebrack [161], 
CRP correlated significantly with several measures of the extent and 
severity of CAD, but the degree of correlation was low, suggesting that 
other factors are more important in determining CRP levels. Moreover, 
the multivariate adjustment resulted in little change in the HR (CRP 
levels & adverse events), arising the concept that C-reactive protein 
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retains predictive value and contributes independently and additively to 
risk prediction with respect to extent/severity CAD. 
However, the predictive value of CRP in CSA might not be universal. 
Schnabel [162], on behalf of the Atherogene Investigators, reported that 
hs-CRP is a weaker predictor compared to IL-18, myeloperoxidase, or 
soluble CD40 ligand, after full adjustment. Authors stated that their data 
data do not support the hypothesis that the additional assessment of hs-
CRP leads to better risk stratification compared with Nt-proBNP alone.  
Current guidelines on the management of CSA patients [92] remain 
reluctant concerning the use of biomarkers in daily practice. The fact 
that they might fluctuate over time, abscense of information about 
whether they can change current management strategies or treatments, 
the problem of the cost and availability have severely limited their use. 
However, biomarkers might have a role in selected patients for decision 
making and further research is welcome in this regard. 
Recently, an American Heart Association Scientific Statement 
concerning the criteria for evaluation of novel markers of cardiovascular 
risk has been published by Hlatky and colleagues [163]. The document 
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provides a practical framework for assessing the value of novel markers 
of risk by using a 6-phase protocol. In this regard, PAPP-A has “passed” 
the proof of concept, as values differ –as shown above- in subjects with 
adverse outcome compared to those without (phase 1). PAPP-A has 
been also proven to be independently associated with future adverse 
clinical outcomes in several prospective cohort studies in different 
clinical scenarios (phase 2). Conversely, however, PAPP-A has not been 
shown to improve risk prediction over and above that of traditional risk 
factors, since no significant changes in AUC after addition of PAPP-A 
has been demonstrated (phase 3). No studies –to date- have assessed the 
incremental value of PAPP-A with reclassification methodology. 
Finally, the clinical utility of PAPP-A regarding its ability to change 
patient management and whether the use of this circulating marker is 
able to improve clinical outcome have not been demonstrated so far 
(phases 4,5 & 6).  
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10.5. FINAL CONCLUSSIONS. 
 
1. Our study illustrates an association between PAPP-A levels and all-
cause mortality during long-term follow-up in CSA patients undergoing 
diagnostic coronary arteriography.  
2. In our study PAPP-A was the strongest predictor of all-cause 
mortality, after age and CRP, followed by revascularization at index 
hospitalization, vessel score, creatinine and LVEF.  
3. Of importance, we showed for the first time the existence of a 
threshold effect regarding PAPP-A levels that may be useful in the 
prediction of clinical outcome.  
4. However, the determination of PAPP-A in CSA patients did not 
improve the discrimination ability –as assessed with Harrell’s C 
statistic- or the calibration –as evaluated with Hosmer-Lemeshow test- 
when compared to the model that included traditional risk factors.   
5. The determination of pro-MBP circulating levels and the ratio PAPP-
A/proMBP did not appear to be associated with an adverse outcome 
(all-cause mortality) in CSA patients.  
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6. In our study the independent predictors of all-cause death were age, 
CRP levels, revascularization at index hospitalization, vessel score, 
creatinine levels and PAPP-A (>4.8 mIU/L) levels.   
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10.6. CONCLUSIONES FINALES.  
1. El presente estudio ilustra la existencia de una asociación 
independiente entre los niveles de PAPP-A y la muerte por cualquier 
causa a largo plazo, en pacientes con angina crónica estable remitidos 
para coronariografía diagnóstica, con motivo de estratificación de 
riesgo.  
2. En este estudio PAPP-A fue el predictor más potente de muerte por 
cualquier causa tras la edad y los niveles de PCR, seguido por necesidad 
de revascularización durante la hospitalización, el número de vasos 
afectos, la creatinina y la fracción de eyección del ventrículo izquierdo.  
3. De importancia y por primera vez, se muestra la existencia de un 
“efecto umbral” para los niveles de PAPP-A que podría ser útil en la 
práctica clínica en la predicción de eventos. 
4. Sin embargo, la determinación de los niveles de PAPP-A no mejoró 
el poder discriminativo ni la calibración respecto del modelo que 
incluyó a los factores de riesgo tradicionalmente usados en 
estratificación en este grupo de pacientes. 
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5. La determinación de los niveles circulantes de pro-MBP o de la razón 
PAPP-A/proMBP no pareció asociarse con un peor desenlace en el 
seguimiento en el presente estudio. 
6. En el presente estudio se identificaron como predictores de muerte 
por cualquier causa la edad, los niveles de CRP, revascularización en la 
hospitalización inicial, el número de vasos significativamente afectos 
(vessel score), niveles de creatinina y los niveles altos de PAPP-A (> 
4.8 mIU/L).  
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10.9. TABLES. 
Table 1. Evidences  supporting  a  role  for PAPP-A as a  marker  of  
cardiovascular risk. 
 
 
ACS = Acute coronary syndrome; BTA ELISA = Biotin-tyramide-amplified enzyme 
immunoassay; min = minutes; ND = Not Determined; NR = Not reported; NSTEACS 
= Non-ST-segment elevation acute coronary syndrome; POC Assay = Point-of-care 
time-resolved immunofluorometric assay; Roche Elecsys = Elecsys 2010 assay 
system, Roche Diagnostics; STEMI = ST-segment elevation myocardial infarction; 
US-DSL ELISA = Ultrasensitive Diagnostic Systems Laboratory ELISA. 
 
* Time from symptoms onset to first blood sampling. 
† Chest pain, epigastric pain, unexplained shortness of breath or syncope. 
Authors Condition n PAPP-A 
Time of 
sample* 
Type 
of 
assay 
Endpoint 
OR/ 
HR 
95 % 
CI 
P 
Laterza  
et al 
(124) 
Symptoms 
suggestive 
of ACS†  
346 Continuous 9 hours 
 
US-
DSL 
ELISA 
 
30-day death,  
MI and 
revascularization 
ND 
‡ 
ND ND 
Elesber  
et al 
(123) 
Acute 
chest 
pain** 
59 Continuous NR 
 
US-
DSL 
ELISA 
 
Final diagnosis 
of ACS 
2.09 
1.03-
4.2 
.039 
Heeschen 
et al 
(112) 
NSTEACS 547 
> 12.6 
mIU/L 
8.7 ± 
4.9 
hours 
Roche 
Elecsys 
6-month death 
and  
non fatal MI 
2.33 
1.3-
4.2 
.005 
Lund  
et al 
(111) 
Suspected 
ACS 
136 
≥ 2.9 
mIU/L 
NR 
POC 
Assay 
 
6-month 
cardiovascular 
mortality, non-
fatal MI or 
revascularization 
4.6 
1.8-
11.8 
.002 
Lund  
et al 
(126) 
STEMI 62 
> 10  
mIU/L 
150  
(90-300) 
min.a 
POC  
Assay 
12-month 
cardiovascular 
mortality or 
non-fatal MI. 
NDb ND .049 
Future deathc 5.29 
1.2-
22 
.023 Elesber  
et al 
(120) 
Chronic 
Stable 
Angina 
103 Continuous - 
BTA 
ELISA Future death and 
ACSc 
3.56 
1.2-
10 
.015 
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‡ A cut-off point of 0.22 mIU/L was reported to show a sensitivity of 66.7 % (95 % CI 
48.2-82) and specificity 51.1 % (95 % CI 45.4-56.8).  
** Intermediate to high risk of ACS. 
a Median and interquartile range. 
b Cumulative risk was 15% if PAPP-A levels <3 mIU/L, 20% if PAPP-A 3-10 mIU/L 
and 45% if PAPP-A > 10mIU/L (data coming from an unadjusted Kaplan-Meier 
method). 
c Median follow-up was 4.9 and interquartile range 1.1-5.9 (years). 
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Table 2. Baseline characteristics of patients in the lowest quartile of 
PAPP-A levels (Group 1, ≤4.6 mIU/L) vs. remaining quartiles (Group 2, 
>4.6 mIU/L).  
Variable 
Total 
Cohort 
(n = 663) 
Group 1 
PAPP-A 
≤4.6 mIU/L
*
 
(n=175) 
Group 2 
PAPP-A 
>4.6 mIU/L
§
 
(n=488) 
P 
Age, mean ± SD 62.9 ± 9.7 60.9 ± 8.9 63.7 ± 9.9 < 0.01 
Male, n (%) 494 (74) 103 (58.9) 391 (80.1) < 0.01 
BMI, median (Q1, Q3) 27 (24-30) 27 (24-31) 27 (24-29) 0.31 
Systolic blood pressure, 
(mmHg), mean ± SD 
134 ± 20 132 ± 20 134 ± 20 0.12 
Diastolic blood pressure, 
(mmHg), mean ± SD 
80 ± 11 80 ± 10 80 ± 11 0.35 
High CCS class, n (%) # 127 (19) 35 (20) 92 (19) 0.72 
Cardiovascular risk 
factors 
    
Family history of CAD, 
 n (%) 
348 (52) 104 (59) 244 (50) 0.03 
Current smoking, n (%) 191 (29) 42 (24) 149 (30.5) 0.11 
Diabetes mellitus, n (%) 41 (6) 10 (5.7) 31 (6.4) 0.76 
Hyperlipidemia, n (%) 273 (41) 84 (48) 189 (38.8) 0.03 
Hypertension, n (%) 209 (31) 45 (25.7) 164 (33.6) 0.05 
Previous MI, n (%) 250 (38) 63 (36) 187 (38.3) 0.58 
Prior PTCA, n (%) 53 (8) 10 (5.7) 43 (8.8) 0.19 
Biochemistry     
Total cholesterol, 
(mmol/L), mean ± SD 
5.85 ± 1.16 5.92 ± 1.31 5.82 ± 1.09 0.44 
HDL-cholesterol, 
(mmol/L), median 
(Q1,Q3) 
1.22 ± 0.89 1.16 ± 0.65 1.26 ± 1 0.67 
LDL-cholesterol, 
(mmol/L), mean ± SD 
3.78 ± 1.60 3.86 ± 1.52 3.74 ± 1.65 0.55 
Creatinine, 
(µmol/L), median  
Q1, Q3) 
82 (82-82) 78 (73-85) 88 (75-102) < 0.01 
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Triglycerides,(mmol/L),  
median (Q1, Q3) 
1.5 (1-2.1) 1.5 (1.1-2.2) 1.4 (1-2) 0.32 
C-reactive protein, 
(mg/L), median (Q1, Q3) 
2.3  
(1.1-4.6) 
2.6  
(1-4.6) 
2.2 
 (1.1-4.7) 
0.84 
Cardiac catheterization     
Number of vessels **, 
median (Q1, Q3) 
2 (1-2) 1 (0-2) 2 (1-2) < 0.01 
Total extension score, 
median (Q1, Q3) † 
17 (8-28) 12 (4-25) 18 (10-29) < 0.01 
LVEF, (%) mean ± SD 65.7 ± 10.9 67.9 ± 8.7 64.9 ± 11.4 < 0.01 
Revascularization at index 
hospitalization,n (%) 
116 (17.5) 30 (14.7) 86 (18.7) 0.21 
Treatment at discharge     
Aspirin 
at discharge, n (%) 
530 (80) 136 (78) 394 (81) 0.39 
Betablocker 
at discharge, n (%) 
353 (53) 98 (56) 255 (52) 0.39 
Lipid lowering drugs 
at discharge, n (%) 
96 (14) 31 (18) 65 (13) 0.15 
ACE inhibitors 
at discharge, n (%) 
122 (18) 31 (18) 91 (18) 0.78 
CCB 
at discharge, n (%) 
263 (40) 68 (39) 195 (40) 0.79 
All-cause death, n (%) 106 (16) 14 (8.5) 92 (20) < 0.01 
 
 
 
* Range 1.2-4.6 mIU/L ; § Range 4.61-17.2 mIU/L. 
# stratified by the median (CCS > 2), ** “vessel score” = number of vessels with ≥ 75 
% reduction in lumen diameter , † Sullivan extension score. 
Continuous variables are presented as mean values ± standard deviation (SD) or 
median (interquartile range Q1-Q3) (p values for Mann-Whitney test). Categorical 
variables are presented as percentage. 
ACE = Angiotensin converting enzyme; BMI = Body Mass Index; CAD = Coronary 
artery disease; CCB = Calcium channel blocker; CCS = Canadian Cardiovascular 
Society; HDL = High density lipoprotein; LDL = Low density lipoprotein; LVEF = 
Left ventricular ejection fraction; MI = Myocardial infarction; PTCA = Percutaneous 
transluminal coronary angioplasty; SD = Standard deviation. 
Reproduced with permission from Consuegra-Sanchez L et al. Clin Chim Acta 
2008;391:18-23 (ref. 153). 
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Table 3. Baseline characteristics of patients with and without events. 
 
Variable 
Events  
(n=106) 
No events 
(n=518) 
P 
Age, mean ± SD  68.2 ± 8.3 62.1 ± 9.4 < 0.01 
Male, n (%) 82 (77) 390 (75) 0.65 
BMI, median (Q1, Q3) 27 (24-29) 27 (24-30) 0.37 
Systolic blood pressure, 
(mmHg), mean ± SD 
139 ± 20 133 ± 20 < 0.01 
Diastolic blood pressure, 
(mmHg), mean ± SD 
81 ± 10 80 ± 11 0.25 
High CCS class, n (%) * 28 (26) 93 (18) 0.04 
Cardiovascular  
risk factors 
   
Family history of CAD, n (%) 50 (47) 275 (53) 0.26 
Current smoking, n (%) 41 (39) 141 (27) 0.02 
Diabetes mellitus, n (%) 10 (9) 27 (5) 0.09 
Hyperlipidemia, n (%) 32 (30) 228 (44) < 0.01 
Hypertension, n (%) 44 (41) 154 (30) 0.02 
Previous MI, n (%) 51 (48) 185 (36) 0.01 
Prior PTCA, n (%) 9 (8) 42 (8) 0.89 
Biochemistry    
Total cholesterol,  
(mmol/L), mean ± SD 
6.12 ± 1.41 5.81 ± 1.08 0.10 
HDL-cholesterol,  
(mmol/L), median (Q1,Q3) 
0.9 (0.7-1.2) 1.1 (0.8-1.3) 0.12 
LDL-cholesterol,  
(mmol/L), mean ± SD 
4.20 ± 2.12 3.66 ± 1.49 0.13 
Creatinine,  
(µmol/L) mean  ± SD 
89 ± 30 83 ± 11 < 0.01 
Triglycerides,  
(mmol/L),  
median (Q1, Q3) 
1.4 (1.1-2.1) 1.5 (1-2.1) 0.90 
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C-reactive protein,  
(mg/L), median (Q1, Q3) 
3 (2.1-6.7) 2.1 (1-4.2) < 0.01 
PAPP-A (mIU/L),  
median (Q1-Q3) 
5.9 (5.1-7.3) 5.5 (4.5-6.7) < 0.01 
Cardiac catheterization    
Number of vessels §,  
median (Q1, Q3) 
2 (1-3) 1 (1-2) < 0.01 
Total extension score,  
median (Q1, Q3) # 
21 (12-33) 17 (8-27) < 0.01 
LVEF, (%), mean ± SD 61.2 ± 13.9 66.5 ± 10.1 < 0.01 
Revascularization at index 
hospitalization,n (%) 
12 (11.3) 99 (19.1) 0.05 
Treatment at discharge    
Aspirin  
at discharge, n (%) 
78 (73) 420 (81) 0.08 
Betablocker  
at discharge, n (%)  
58 (55) 276 (53) 0.79 
Lipid lowering drugs  
at discharge, n (%) 
14 (13) 77 (15) 0.66 
ACE inhibitors  
at discharge, n (%)  
27 (25) 90 (17) 0.05 
CCB  
at discharge, n (%) 
50 (47) 207 (40) 0.17 
 
* stratified by the median (CCS > 2), § “vessel score” = number of vessels with ≥ 75 % 
reduction in lumen diameter, # Sullivan extension score. 
Continuous variables are presented as mean values ± standard deviation (SD) or 
median (interquartile range Q1-Q3) (p values for Mann-Whitney test). Categorical 
variables are presented as percentage.ACE = Angiotensin converting enzyme; BMI = 
Body Mass Index; CAD = Coronary artery disease; CCB = Calcium channel blocker; 
CCS = Canadian Cardiovascular Society; HDL = High density lipoprotein; LDL = 
Low density lipoprotein; LVEF = Left ventricular ejection fraction; MI = Myocardial 
infarction; PTCA = Percutaneous transluminal coronary angioplasty; SD = Standard 
deviation. Reproduced with permission from Consuegra-Sanchez L et al. Clin Chim 
Acta 2008;391:18-23 (ref. 153). 
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Table 4.  Independent predictors of adverse outcome in patients with 
CSA (multivariable Cox model). 
 
 HR# 95% CI P value 
PAPP-A* 1.953 1.135-3.360 0.016 
Age (years) 1.051 1.026-1.077 <0.001 
CRP (mg/L) 1.414 1.183-1.690 <0.001 
Revascularization 
at index 
hospitalization 
0.513 0.273-0.963 0.038 
Vessel Score 
(points) 
1.290 1.031-1.615 0.026 
Creatinine 
(µmol/L) 
1.009 1.002-1.016 0.010 
LVEF 
(percent units) 
0.986 0.971-1.001 0.065 
 
 
CI = Confidence interval; CRP = C-Reactive protein; HR = Hazard ratio; LVEF = 
Left-ventricular ejection fraction.  
* PAPP-A > 4.8 mIU/L. # multivariately adjusted (age, gender,  hypertension,  
hyperlipidaemia,  creatinine,  vessel score,  Sullivan extension score, LVEF, type 2 
diabetes mellitus, revascularization at index hospitalization and CRP).
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Table 5.  Model Calibration (Hosmer-Lemeshow test). 
 
 Chi-square value P value 
Without PAPP-A 2.705 0.951 
With PAPP-A 5.393 0.715 
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Table 6. Bootstrapping method. 
 
Replications HR* 95% CI 
0 1.95 1.13-3.36 
25 1.95 1.04-3.04 
50 1.95 0.99-3.21 
75 1.95 1.02-3.11 
100 1.95 1.02-3.10 
150 1.95 0.97-3.27 
500 1.95 0.96-3.30 
1000 1.95 0.98-3.25 
3000 1.95 0.97-3.29 
4000 1.95 0.97-3.29 
 
 
* adjusted by age, gender,  hypertension,  hyperlipidaemia,  creatinine,  vessel score,  
Sullivan extension score, LVEF, type 2 diabetes mellitus, revascularization at index 
hospitalization and CRP. 
CI = Confidence interval; HR = Hazard ratio (PAPP-A > 4.8 mIU/L). 
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10.10. FIGURES. 
 
Figure 1. 
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Figure 2. 
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Figure 3. 
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 Figure 4. Inflammation links classic risk factors to altered cellular behavior 
within the arterial wall and secretion of inflammatory markers in the 
circulation. Primary proinflammatory risk factors elicit the expression of 
primary proinflammatory cytokines that can be released directly into the 
blood. Cytokines orchestrate the production of adhesion molecules, matrix 
metalloproteinases, and reactive oxygen species that may also be released from 
lesions. Reprinted with permission from ref. 80. 
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Figure 5. The plot shows that complex stenoses progress significantly 
more than smooth stenoses (11.6 ± 17.5% vs 3.9 ± 10.2%, change from 
baseline; Coronary arteriography was repeated at 8 ± 3 months' follow-
up). From Kaski JC et al. Circulation. 1995;92:2058-65. Reproduced 
with permission. 
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Figure 6. Error bars showing mean (95% CI) PAPP-A levels in patients 
without coronary disease (no CAD), patients with single vessel disease 
(single-VD) and those with multi-VD. From Cosin-Sales J et al. Eur 
Heart J. 2005;26:2093-8. Reproduced with permission. 
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Figure 7. PAPP-A levels after PCI (above) and ST elevation ACS 
(below). Reproduced with permission from Iversen et al, Am J Cardiol. 
2008;101:1389-94. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACS = Acute coronary syndrome; CKMB = Creatinkinase isoenzyme MB; PCI = 
Percutaneous coronary intervention. 
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 Figure 8. Summary of preclinical, histopathological and clinical 
evidences of PAPP-A in cardiovascular medicine. Reproduced with 
permission from Consuegra-Sánchez L et al, Drug News Perspect. 2009 
(in press, 98). 
 
 
 
 
 
 
 
Please see text for references. 
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Figure 9. Pregnancy associated plasma protein (PAPP-A) is commonly 
analysed using immunoassays employing an antigen “sandwich” format. 
An antibody is normally attached to a solid phase base of a plastic tube 
or well of a microtitreplate. A detection antibody, which is labelled with 
an enzyme or a fluorochromic molecule, then binds to the captured 
antigen. The most widely used assays detects and quantifies total PAPP-
A (A) i.e. free PAPP-A plus the PAPP-A/proMBP complex. (B) An 
assay has been developed to specifically measure the PAPP-A/proMBP 
complex, and when used in conjunction with the total assay may 
provide a derived value for free PAPP-A. (C) A direct assay for free 
PAPP-A would be the ideal approach to investigate PAPP-A in 
cardiovascular disease. Reproduced with permission from Consuegra-
Sanchez L et al. Atherosclerosis 2009;203:346-52 (ref. 97). 
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Figure 10. The Kaplan Meier curves of survival according to PAPP-A 
quartiles in mIU/L (Q1 = 1st quartile ≤ 4.6; Q2 = 2nd quartile 4.6-5.6; Q3 
= 3rd quartile 5.6-6.8; Q4 = 4th quartile ≥ 6.8). Reproduced with 
permission from Consuegra-Sanchez L et al. Clin Chim Acta 
2008;391:18-23 (ref. 153). 
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Figure 11. Fractional Polynomial analysis supporting a “threshold 
effect” (4.8mUI/L, P30) of PAPP-A levels in relation to adverse 
outcome, in patients with CSA. 
 
 
 
Covariates were age, gender,  hypertension,  hyperlipidaemia,  creatinine,  vessel 
score,  Sullivan extension score, LVEF, type 2 diabetes mellitus, revascularization at 
index hospitalization and CRP. 
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Figure 12. Log-minus-log curves to test the proportional hazard 
assumption. 
 
 
Q1 to Q4 = Quartiles of PAPP-A levels at study entry. 
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Figure 13A & B. The Receiver Operating Characteristic (ROC) curves 
of PAPP-A levels (left) and the multivariable model with and without 
the incorporation of PAPP-A (right, p = non-significant). 
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Figure 14. Hazard ratios (HR) for all-cause death according to baseline 
levels of CRP and PAPP-A in combined analysis. The relative risk and 
95% CI for the patients is provided. 
 
 
 
Note: The HR is adjusted by age, gender,  hypertension,  hyperlipidaemia,  creatinine,  
vessel score,  Sullivan extension score, LVEF, type 2 diabetes mellitus and 
revascularization at index hospitalization. 
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Figure 15 A & B. Kaplan-Meier curves of survival according to pro-
MBP (left) & PAPP-A/pro-MBP ratio (right) quartiles at study entry. 
 
 
 
 
 
 
 
 
 
